Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 584 articles:
HTML format
Text format



Single Articles


    May 2018
  1. CHARLES KA, Naudet F, Bouali-Benazzouz R, Landry M, et al
    Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease.
    Mov Disord. 2018 May 18. doi: 10.1002/mds.27377.
    PubMed     Text format     Abstract available


  2. LI J, Ruskey JA, Arnulf I, Dauvilliers Y, et al
    Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27385.
    PubMed     Text format     Abstract available


  3. DU G, Lewis MM, Sica C, He L, et al
    Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27318.
    PubMed     Text format     Abstract available


  4. TANIGUCHI D, Hatano T, Kamagata K, Okuzumi A, et al
    Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27365.
    PubMed     Text format     Abstract available


  5. HELDMANN M, Heeren J, Klein C, Rauch L, et al
    Neuroimaging abnormalities in individuals exhibiting Parkinson's disease risk markers.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27313.
    PubMed     Text format     Abstract available


  6. MEROLA A, Romagnolo A, Lopiano L, Espay AJ, et al
    Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer?"
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27421.
    PubMed     Text format    


  7. DE PABLO-FERNANDEZ E, Warner TT
    Autonomic dysfunction in Parkinson's disease: The hidden game changer?
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27422.
    PubMed     Text format    


  8. BAUFRETON J, Milekovic T, Li Q, McGuire S, et al
    Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27404.
    PubMed     Text format     Abstract available


  9. LEWIS MM, Du G, Baccon J, Snyder AM, et al
    Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27381.
    PubMed     Text format     Abstract available


  10. ORTUNO-LIZARAN I, Beach TG, Serrano GE, Walker DG, et al
    Phosphorylated alpha-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.
    Mov Disord. 2018 May 8. doi: 10.1002/mds.27392.
    PubMed     Text format     Abstract available


  11. LEWITT PA
    Comment on 'Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease' by Hiller et al.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27379.
    PubMed     Text format    


  12. CEDARBAUM JM
    Elephants, Parkinson's disease, and proof-of-concept clinical trials.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27398.
    PubMed     Text format    


    April 2018
  13. LIPSMEIER F, Taylor KI, Kilchenmann T, Wolf D, et al
    Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27376.
    PubMed     Text format     Abstract available


  14. SARDI SP, Cedarbaum JM, Brundin P
    Targeted therapies for Parkinson's disease: From genetics to the clinic.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27414.
    PubMed     Text format     Abstract available


  15. HANGANU A, Houde JC, Fonov VS, Degroot C, et al
    White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease.
    Mov Disord. 2018 Apr 23. doi: 10.1002/mds.27364.
    PubMed     Text format     Abstract available


  16. LEFAIVRE SC, Brown MJN, Almeida QJ
    Does cerebellar overactivity contribute to gait and balance deficits in Parkinson's disease?
    Mov Disord. 2018 Apr 20. doi: 10.1002/mds.27396.
    PubMed     Text format    


  17. MESTRE TA, Pont-Sunyer C, Kausar F, Visanji NP, et al
    Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mov Disord. 2018 Apr 17. doi: 10.1002/mds.27272.
    PubMed     Text format     Abstract available


  18. CONTARINO MF, Marinus J, van Hilten JJ
    Does deep brain stimulation of the subthalamic nucleus prolong survival in Parkinson's Disease?
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27384.
    PubMed     Text format    


  19. FRIEDMAN JH
    Quetiapine for Parkinson's Disease psychosis: Evidence-based medicine versus expert belief: A case study.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27378.
    PubMed     Text format    


  20. LANG AE, Espay AJ
    Disease modification in Parkinson's Disease: Current approaches, challenges, and future considerations.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27360.
    PubMed     Text format     Abstract available


  21. KASTEN M, Hartmann C, Hampf J, Schaake S, et al
    Genotype-phenotype relations for the Parkinson's Disease genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27352.
    PubMed     Text format     Abstract available


  22. AMANAT M, Salehi M
    Glitazone in Parkinson's Disease.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27397.
    PubMed     Text format    


  23. SCOTT KM, Williams-Gray CH
    Targeting aged astrocytes may be a new therapeutic strategy in Parkinson's disease.
    Mov Disord. 2018 Apr 6. doi: 10.1002/mds.27387.
    PubMed     Text format    


    March 2018
  24. MACEROLLO A, Brown MJN
    Beta oscillations and indirect pathway spiny projecting neurons: A selective neuronal mechanism linked to Parkinsonian pathophysiology?
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27388.
    PubMed     Text format    


  25. WEIR S, Samnaliev M, Kuo TC, Tierney TS, et al
    Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27302.
    PubMed     Text format     Abstract available


  26. KORDOWER JH, Burke RE
    Disease modification for Parkinson's disease: Axonal regeneration and trophic factors.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27383.
    PubMed     Text format     Abstract available


  27. COSSU G, Melis M, Sarchioto M, Melis M, et al
    6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27391.
    PubMed     Text format     Abstract available


  28. LITVAN I, Kieburtz K, Troster AI, Aarsland D, et al
    Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27345.
    PubMed     Text format     Abstract available


  29. KADHIM S, Pringsheim T, Le A, Fiest KM, et al
    Validating screening tools for depression in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27371.
    PubMed     Text format    


  30. MOGHADDAM HS, Arabi MH
    Synaptotagmin-11 Is a novel hotspot in the pathogenesis of parkin-linked Parkinson's disease: New implications for clinical targeting.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27369.
    PubMed     Text format    


  31. HOUSER MC, Chang J, Factor SA, Molho ES, et al
    Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27326.
    PubMed     Text format     Abstract available


  32. SIMUNI T, Siderowf A, Lasch S, Coffey CS, et al
    Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27361.
    PubMed     Text format     Abstract available


  33. FOX SH, Katzenschlager R, Lim SY, Barton B, et al
    International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27372.
    PubMed     Text format     Abstract available


  34. FASANO A, De Vloo P, Llinas M, Hlasny E, et al
    Magnetic resonance imaging-guided focused ultrasound thalamotomy in Parkinson tremor: Reoperation after benefit decay.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27348.
    PubMed     Text format    


  35. ANTONINI A, Moro E, Godeiro C, Reichmann H, et al
    Medical and surgical management of advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27340.
    PubMed     Text format     Abstract available


  36. FERNANDEZ HH, Boyd JT, Fung VSC, Lew MF, et al
    Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27338.
    PubMed     Text format     Abstract available


  37. HEINZEL S, Kasten M, Behnke S, Vollstedt EJ, et al
    Age- and sex-related heterogeneity in prodromal Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27349.
    PubMed     Text format    


  38. WEINTRAUB D, Troster AI, Marras C, Stebbins G, et al
    Initial cognitive changes in Parkinson's disease.
    Mov Disord. 2018 Mar 15. doi: 10.1002/mds.27330.
    PubMed     Text format     Abstract available


  39. CARDOSO F
    Vitamin B12 and Parkinson's disease: What is the relationship?
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27366.
    PubMed     Text format    


  40. BECK G, Maehara S, Chang PL, Papa SM, et al
    A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27341.
    PubMed     Text format     Abstract available


  41. CHRISTINE CW, Auinger P, Joslin A, Yelpaala Y, et al
    Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27301.
    PubMed     Text format     Abstract available


  42. PALMA JA, Kaufmann H
    Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.
    Mov Disord. 2018;33:372-390.
    PubMed     Text format     Abstract available


    February 2018
  43. SONG W, Kothari V, Velly AM, Cressatti M, et al
    Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27328.
    PubMed     Text format     Abstract available


  44. GOLDMAN JG, Holden SK, Litvan I, McKeith I, et al
    Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27323.
    PubMed     Text format     Abstract available


  45. MORALES-BRICENO H, Sanchez-Hernandez BE, Meyer E, Kurian MA, et al
    Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27294.
    PubMed     Text format    


  46. CENCI MA, Crossman AR
    Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27337.
    PubMed     Text format     Abstract available


  47. MENG Y, Voisin MR, Suppiah S, Kalia SK, et al
    Is there a role for MR-guided focused ultrasound in Parkinson's disease?
    Mov Disord. 2018 Feb 24. doi: 10.1002/mds.27308.
    PubMed     Text format    


  48. WEIL RS, Schwarzkopf DS, Bahrami B, Fleming SM, et al
    Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27311.
    PubMed     Text format     Abstract available


  49. PERAN P, Barbagallo G, Nemmi F, Sierra M, et al
    MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27307.
    PubMed     Text format     Abstract available


  50. ARGAUD S, Verin M, Sauleau P, Grandjean D, et al
    Facial emotion recognition in Parkinson's disease: A review and new hypotheses.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27305.
    PubMed     Text format     Abstract available


  51. FERNANDEZ-SANTIAGO R, Garrido A, Infante J, Gonzalez-Aramburu I, et al
    alpha-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27295.
    PubMed     Text format     Abstract available


  52. DAFSARI HS, Silverdale M, Strack M, Rizos A, et al
    Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2018 Feb 21. doi: 10.1002/mds.27283.
    PubMed     Text format     Abstract available


  53. FEDERICO A, Tinazzi M, Tamburin S
    MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27329.
    PubMed     Text format    


  54. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27339.
    PubMed     Text format    


  55. WYMAN-CHICK KA, Martin PK, Weintraub D, Sperling SA, et al
    Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27335.
    PubMed     Text format     Abstract available


  56. PARK JS, Koentjoro B, Klein C, Sue CM, et al
    Single heterozygous ATP13A2 mutations cause cellular dysfunction associated with Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27327.
    PubMed     Text format    


  57. SAMOTUS O, Parrent A, Jog M
    Spinal cord stimulation therapy for gait dysfunction in advanced Parkinson's disease patients.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.
    PubMed     Text format     Abstract available


  58. FAZIO P, Svenningsson P, Cselenyi Z, Halldin C, et al
    Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27316.
    PubMed     Text format     Abstract available


  59. BOUCA-MACHADO R, Lennaerts-Kats H, Bloem B, Ferreira JJ, et al
    Why palliative care applies to Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27309.
    PubMed     Text format    


  60. DAGAN M, Herman T, Harrison R, Zhou J, et al
    Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300.
    PubMed     Text format     Abstract available


  61. PALMA JA
    Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27347.
    PubMed     Text format    


  62. ABBASI N, Mohajer B, Abbasi S, Hasanabadi P, et al
    Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27284.
    PubMed     Text format     Abstract available


  63. MULAK A
    A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27304.
    PubMed     Text format    


  64. MAHLKNECHT P, Gasperi A, Djamshidian A, Kiechl S, et al
    Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27281.
    PubMed     Text format     Abstract available


  65. BAHIRAEE A, Ebrahimi R
    A noble pathological role for alpha-synuclein in triggering neurodegeneration of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27306.
    PubMed     Text format    


  66. CREED RB, Goldberg MS
    New developments in genetic rat models of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27296.
    PubMed     Text format     Abstract available


  67. WEINTRAUB D, Hamilton JL, Eberling J, Litvan I, et al
    At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27310.
    PubMed     Text format    


  68. LAGRAVINESE G, Pelosin E, Bonassi G, Carbone F, et al
    Gait initiation is influenced by emotion processing in Parkinson's disease patients with freezing.
    Mov Disord. 2018 Feb 2. doi: 10.1002/mds.27312.
    PubMed     Text format     Abstract available


  69. NAROS G, Grimm F, Weiss D, Gharabaghi A, et al
    Directional communication during movement execution interferes with tremor in Parkinson's disease.
    Mov Disord. 2018;33:251-261.
    PubMed     Text format     Abstract available


    January 2018
  70. NOYCE AJ, Dickson J, Rees RN, Bestwick JP, et al
    Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27282.
    PubMed     Text format     Abstract available


  71. MOREAU C, Duce JA, Rascol O, Devedjian JC, et al
    Iron as a therapeutic target for Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27275.
    PubMed     Text format    


  72. PAL G, Ouyang B, Verhagen L, Serrano G, et al
    Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27280.
    PubMed     Text format    


  73. CHEN V, Saez-Atienzar S
    A tango for two: Dopamine and alpha-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27248.
    PubMed     Text format    


  74. SAVICA R, Grossardt BR, Rocca WA, Bower JH, et al
    Parkinson disease with and without Dementia: A prevalence study and future projections.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27277.
    PubMed     Text format     Abstract available


  75. HIMMELBERG MM, West RJH, Wade AR, Elliott CJH, et al
    A perceptive plus in Parkinson's disease.
    Mov Disord. 2018 Jan 14. doi: 10.1002/mds.27240.
    PubMed     Text format    


  76. KIM IY, O'Reilly EJ, Hughes KC, Gao X, et al
    Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.
    Mov Disord. 2018 Jan 10. doi: 10.1002/mds.27279.
    PubMed     Text format     Abstract available


  77. GARCIA-SANZ P, Moratalla R
    The importance of cholesterol in Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27251.
    PubMed     Text format    


  78. GAO Y, Wilson GR, Stephenson SEM, Bozaoglu K, et al
    The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27270.
    PubMed     Text format     Abstract available


  79. AHMADI NS
    Mutant parkin-induced parkinsonism from an electrical point of view: Abnormal excitatory response to dopamine resolved after substitution.
    Mov Disord. 2018;33:71.
    PubMed     Text format    


    December 2017
  80. MEROLA A, Romagnolo A, Rosso M, Suri R, et al
    Autonomic dysfunction in Parkinson's disease: A prospective cohort study.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27268.
    PubMed     Text format     Abstract available


  81. MARRINAN SL, Otiker T, Vasist LS, Gibson RA, et al
    A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27259.
    PubMed     Text format     Abstract available


  82. BOWER JH, Grossardt BR, Rocca WA, Savica R, et al
    Prevalence of and indications for antipsychotic use in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27256.
    PubMed     Text format     Abstract available


  83. LIU Z, Tang B
    Novel Parkinson's disease risk loci identified through a meta-analysis of genome-wide association studies.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27276.
    PubMed     Text format    


  84. BOUTHOUR W, Wegrzyk J, Momjian S, Peron J, et al
    Short pulse width in subthalamic stimulation in Parkinson's disease: a randomized, double-blind study.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27265.
    PubMed     Text format     Abstract available


  85. ROOSEN DA, Singleton AB
    Leucine rich repeat kinase knockout (LRRK KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease.
    Mov Disord. 2017 Dec 19. doi: 10.1002/mds.27267.
    PubMed     Text format    


  86. PICCONI B, Hernandez LF, Obeso JA, Calabresi P, et al
    Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Mov Disord. 2017 Dec 8. doi: 10.1002/mds.27261.
    PubMed     Text format     Abstract available


  87. GOLDMAN JG, Andrews H, Amara A, Naito A, et al
    Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27232.
    PubMed     Text format     Abstract available


  88. KIEBURTZ K, Katz R, Olanow CW
    New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27220.
    PubMed     Text format    


  89. FERNANDES HJR
    Beyond the lysosome: Cholesterol role on endoplasmic reticulum and lipid droplets in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27249.
    PubMed     Text format    


  90. PADMANABHAN S, Burke RE
    Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27209.
    PubMed     Text format    


    November 2017
  91. LOZANO CS, Tam J, Lozano AM
    The changing landscape of surgery for Parkinson's Disease.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27228.
    PubMed     Text format     Abstract available


  92. BHATIA KP, Bain P, Bajaj N, Elble RJ, et al
    Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27121.
    PubMed     Text format     Abstract available


  93. SVENSSON E, Henderson VW, Szepligeti S, Stokholm MG, et al
    Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study.
    Mov Disord. 2017 Nov 29. doi: 10.1002/mds.27253.
    PubMed     Text format     Abstract available


  94. BUARD I, Sciacca DM, Martin CS, Rogers S, et al
    Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Nov 27. doi: 10.1002/mds.27246.
    PubMed     Text format    


  95. TROPEA TF, Xie SX, Rick J, Chahine LM, et al
    APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27204.
    PubMed     Text format     Abstract available


  96. KOHSAKA M, Oeda T, Umemura A, Tomita S, et al
    Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27243.
    PubMed     Text format    


  97. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27233.
    PubMed     Text format     Abstract available


  98. KULIKOVSKAJA L, Seibler P
    Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27262.
    PubMed     Text format    


  99. STEIGERWALD F, Timmermann L, Kuhn A, Schnitzler A, et al
    Pulse duration settings in subthalamic stimulation for Parkinson's disease.
    Mov Disord. 2017 Nov 22. doi: 10.1002/mds.27238.
    PubMed     Text format     Abstract available


  100. POCHARD C, Leclair-Visonneau L, Coron E, Neunlist M, et al
    Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27237.
    PubMed     Text format    


  101. WEAVER FM, Stroupe KT, Smith B, Gonzalez B, et al
    Survival in patients with Parkinson's disease after deep brain stimulation or medical management.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27235.
    PubMed     Text format     Abstract available


  102. DAFSARI HS, Reker P, Stalinski L, Silverdale M, et al
    Quality of life outcomes after subthalamic stimulation in Parkinson's disease depends on age.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27222.
    PubMed     Text format     Abstract available


  103. SYRKIN-NIKOLAU J, Neuville R, O'Day J, Anidi C, et al
    Coordinated reset vibrotactile stimulation shows prolonged improvement in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27223.
    PubMed     Text format    


  104. ELAHI E
    PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability.
    Mov Disord. 2017 Nov 16. doi: 10.1002/mds.27126.
    PubMed     Text format    


  105. HELMICH RC
    The cerebral basis of Parkinsonian tremor: A network perspective.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27224.
    PubMed     Text format     Abstract available


  106. GOETZ CG
    Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years?
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27214.
    PubMed     Text format    


  107. ARNALDI D, De Carli F, Fama F, Brugnolo A, et al
    Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27190.
    PubMed     Text format     Abstract available


  108. SCHNEIDER SA, Alcalay RN
    Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
    Mov Disord. 2017;32:1504-1523.
    PubMed     Text format     Abstract available


  109. SCHAPIRA AH
    What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease.
    Mov Disord. 2017;32:1499-1500.
    PubMed     Text format    


    October 2017
  110. SOHAIL S, Yu L, Schneider JA, Bennett DA, et al
    Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27200.
    PubMed     Text format     Abstract available


  111. LI W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, et al
    11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27183.
    PubMed     Text format     Abstract available


  112. METEREAU E, Beaudoin-Gobert M, Duperrier S, Thobois S, et al
    Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Mov Disord. 2017 Oct 27. doi: 10.1002/mds.27201.
    PubMed     Text format     Abstract available


  113. FASANO A, Canning CG, Hausdorff JM, Lord S, et al
    Falls in Parkinson's disease: A complex and evolving picture.
    Mov Disord. 2017 Oct 25. doi: 10.1002/mds.27195.
    PubMed     Text format     Abstract available


  114. WEINTRAUB D, Chahine LM, Hawkins KA, Siderowf A, et al
    Cognition and the course of prodromal Parkinson's disease.
    Mov Disord. 2017 Oct 24. doi: 10.1002/mds.27189.
    PubMed     Text format     Abstract available


  115. FENGLER S, Liepelt-Scarfone I, Brockmann K, Schaffer E, et al
    Cognitive changes in prodromal Parkinson's disease: A review.
    Mov Disord. 2017 Oct 5. doi: 10.1002/mds.27135.
    PubMed     Text format     Abstract available


  116. ASCHERIO A, Schwarzschild MA
    Dietary antioxidants and Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27194.
    PubMed     Text format    


  117. SAEED U, Masellis M
    Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27171.
    PubMed     Text format    


  118. MACLEOD AD, Dalen I, Tysnes OB, Larsen JP, et al
    Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27177.
    PubMed     Text format     Abstract available


  119. WEIL RS, Pappa K, Schade RN, Schrag AE, et al
    The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27176.
    PubMed     Text format    


  120. FORD KJ, Joop A, Memon RA, Wood KH, et al
    Pedestrian safety in patients with Parkinson's disease: A case-control study.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27124.
    PubMed     Text format     Abstract available


  121. STANDAERT DG
    What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.
    Mov Disord. 2017;32:1341-1342.
    PubMed     Text format    


    September 2017
  122. THEVATHASAN W, Debu B, Aziz T, Bloem BR, et al
    Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review.
    Mov Disord. 2017 Sep 28. doi: 10.1002/mds.27098.
    PubMed     Text format     Abstract available


  123. BIUNDO R, Weis L, Abbruzzese G, Calandra-Buonaura G, et al
    Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Mov Disord. 2017 Sep 27. doi: 10.1002/mds.27181.
    PubMed     Text format     Abstract available


  124. TESSITORE A, De Micco R, Giordano A, di Nardo F, et al
    Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27139.
    PubMed     Text format     Abstract available


  125. ROSE SJ, Harrast P, Donsante C, Fan X, et al
    Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27169.
    PubMed     Text format     Abstract available


  126. FULLARD ME, Xie SX, Marek K, Stern M, et al
    Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.
    Mov Disord. 2017 Sep 14. doi: 10.1002/mds.27127.
    PubMed     Text format     Abstract available


  127. SAME K, Ghazi Sherbaf F, Aarabi MH
    New link between Parkinson's and Alzheimer's: Research uncovers the role of mutant leucine rich repeat kinase 2 and amyloid precursor protein.
    Mov Disord. 2017 Sep 13. doi: 10.1002/mds.27170.
    PubMed     Text format    


  128. FRISALDI E, Carlino E, Zibetti M, Barbiani D, et al
    The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
    Mov Disord. 2017 Sep 12. doi: 10.1002/mds.27142.
    PubMed     Text format     Abstract available


  129. YANG F, Wolk A, Hakansson N, Pedersen NL, et al
    Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27120.
    PubMed     Text format     Abstract available


  130. HAN W, Sapkota S, Camicioli R, Dixon RA, et al
    Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27173.
    PubMed     Text format     Abstract available


  131. GHAHREMANI A, Chen R
    Deep brain stimulation modulates the shape of cortical beta oscillations in Parkinson's disease.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27144.
    PubMed     Text format    


  132. EUSEBI P, Giannandrea D, Biscetti L, Abraha I, et al
    Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27110.
    PubMed     Text format     Abstract available


  133. BRAKEDAL B, Flones I, Reiter SF, Torkildsen O, et al
    Glitazone use associated with reduced risk of Parkinson's disease.
    Mov Disord. 2017 Sep 1. doi: 10.1002/mds.27128.
    PubMed     Text format     Abstract available


  134. OBESO JA, Stamelou M, Goetz CG, Poewe W, et al
    Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
    Mov Disord. 2017;32:1264-1310.
    PubMed     Text format     Abstract available



  135. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative
    Mov Disord. 2017;32:e1-e19.
    PubMed     Text format    


    August 2017
  136. TREZZI JP, Galozzi S, Jaeger C, Barkovits K, et al
    Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27132.
    PubMed     Text format     Abstract available


  137. HEINTZ-BUSCHART A, Pandey U, Wicke T, Sixel-Doring F, et al
    The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27105.
    PubMed     Text format     Abstract available


  138. TURCANO P, Mielke MM, Josephs KA, Bower JH, et al
    Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27125.
    PubMed     Text format     Abstract available


  139. PARNETTI L, Paciotti S, Eusebi P, Dardis A, et al
    Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27136.
    PubMed     Text format     Abstract available


  140. BORGHAMMER P
    How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27138.
    PubMed     Text format     Abstract available


  141. OERTEL W, Eggert K, Pahwa R, Tanner CM, et al
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Mov Disord. 2017 Aug 21. doi: 10.1002/mds.27131.
    PubMed     Text format     Abstract available


  142. CHAUDHURI KR, Jenner P
    Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27104.
    PubMed     Text format    


  143. POLLARD EE
    Where we've gone "right" in the Parkinson's community.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27076.
    PubMed     Text format    


  144. ROCCA WA
    The future burden of Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27114.
    PubMed     Text format    


  145. MIYAUE N, Tada S, Ando R, Yabe H, et al
    cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27109.
    PubMed     Text format    


  146. BANDRES-CIGA S, Cookson MR
    Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder?
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27116.
    PubMed     Text format    


  147. GARCIA-SANZ P, Orgaz L, Bueno-Gil G, Espadas I, et al
    N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
    Mov Disord. 2017 Aug 5. doi: 10.1002/mds.27119.
    PubMed     Text format     Abstract available


  148. LILL CM, Klein C
    What would Dr. James Parkinson think today? The role of genetics in Parkinson's disease.
    Mov Disord. 2017;32:1115-1116.
    PubMed     Text format    


    July 2017
  149. CHUNG SJ, Shin JH, Cho KH, Lee Y, et al
    Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27106.
    PubMed     Text format     Abstract available


  150. DELPONT B, Lhommee E, Klinger H, Schmitt E, et al
    Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27101.
    PubMed     Text format     Abstract available


  151. OFORI E, Krismer F, Burciu RG, Pasternak O, et al
    Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Mov Disord. 2017 Jul 17. doi: 10.1002/mds.27100.
    PubMed     Text format     Abstract available


  152. THIBAULT L, Rascol O, Corvol JC, Ferreira J, et al
    New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
    Mov Disord. 2017 Jul 13. doi: 10.1002/mds.27055.
    PubMed     Text format    


  153. PAYAMI H
    The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27099.
    PubMed     Text format     Abstract available


  154. KOJOVIC M, Kassavetis P, Parees I, Georgiev D, et al
    Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27091.
    PubMed     Text format    


  155. CORREIA GUEDES L, Reimao S, Paulino P, Nunes RG, et al
    Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27083.
    PubMed     Text format    


  156. HEINZEL S, Bernhard FP, Roeben B, Nussbaum S, et al
    Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27062.
    PubMed     Text format    


  157. SAEZ-ATIENZAR S, Singleton AB
    Parkinson Disease and Clathrin Coat Dynamics at Synapses, Why Not?
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27097.
    PubMed     Text format    


  158. SONG N, Wang W, Jia F, Du X, et al
    Assessments of plasma ghrelin levels in the early stages of parkinson's disease.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27095.
    PubMed     Text format     Abstract available


  159. HUANG P, Tan YY, Liu DQ, Herzallah MM, et al
    Motor-symptom laterality affects acquisition in Parkinson's disease: A cognitive and functional magnetic resonance imaging study.
    Mov Disord. 2017;32:1047-1055.
    PubMed     Text format     Abstract available


  160. OBESO JA, Trenkwalder C
    What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society.
    Mov Disord. 2017;32:951-954.
    PubMed     Text format    


    June 2017
  161. ZABETIAN CP, Mata IF
    LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Mov Disord. 2017 Jun 28. doi: 10.1002/mds.27081.
    PubMed     Text format    


  162. GOETZ CG, Stebbins GT, Chung KA, Nicholas AP, et al
    Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
    Mov Disord. 2017 Jun 24. doi: 10.1002/mds.27092.
    PubMed     Text format    


  163. LHOMMEE E, Boyer F, Wack M, Pelissier P, et al
    Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
    Mov Disord. 2017 Jun 23. doi: 10.1002/mds.27065.
    PubMed     Text format     Abstract available


  164. STEINER LA, Neumann WJ, Staub-Bartelt F, Herz DM, et al
    Subthalamic beta dynamics mirror Parkinsonian bradykinesia months after neurostimulator implantation.
    Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27068.
    PubMed     Text format     Abstract available


  165. CHOTIBUT T, Meadows S, Kasanga EA, McInnis T, et al
    Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27077.
    PubMed     Text format     Abstract available


  166. BONET-PONCE L, Singleton AB
    Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27078.
    PubMed     Text format    


  167. CLAASSEN DO, Stark AJ, Spears CA, Petersen KJ, et al
    Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.
    Mov Disord. 2017 Jun 19. doi: 10.1002/mds.27047.
    PubMed     Text format     Abstract available


  168. PELOSI A
    Cell-specific alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
    Mov Disord. 2017 Jun 16. doi: 10.1002/mds.27071.
    PubMed     Text format    


  169. FRIEDMAN JH
    Drug-induced parkinsonism.
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27050.
    PubMed     Text format    


  170. ROCCA WA, Savica R, Grossardt BR
    Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27051.
    PubMed     Text format    


  171. HOOGLAND J, Boel JA, de Bie RMA, Geskus RB, et al
    Mild cognitive impairment as a risk factor for Parkinson's disease dementia.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27002.
    PubMed     Text format     Abstract available


  172. TITOVA N, Chaudhuri KR
    Personalized medicine in Parkinson's disease: Time to be precise.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27027.
    PubMed     Text format    


  173. LARSSON SC, Singleton AB, Nalls MA, Richards JB, et al
    No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study.
    Mov Disord. 2017 Jun 8. doi: 10.1002/mds.27069.
    PubMed     Text format     Abstract available


  174. ROSSI A, Berger K, Chen H, Leslie D, et al
    Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27063.
    PubMed     Text format     Abstract available


  175. KASSUBEK J, Huppertz HJ, Hoglinger GU
    Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27057.
    PubMed     Text format    


  176. KUMAR A
    Reprogramming the striatal stars: A new treatment option for Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27067.
    PubMed     Text format    


  177. QUATTRONE A, Nigro S
    MRI measures of brainstem in Parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27056.
    PubMed     Text format    


  178. MAHLKNECHT P, Akram H, Georgiev D, Tripoliti E, et al
    Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27042.
    PubMed     Text format     Abstract available


  179. PINA-FUENTES D, Little S, Oterdoom M, Neal S, et al
    Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.26959.
    PubMed     Text format    



  180. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2017;32 Suppl 2:S1-S1079.
    PubMed     Text format    


  181. MANDEMAKERS W, Quadri M, Stamelou M, Bonifati V, et al
    TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27061.
    PubMed     Text format     Abstract available


  182. PEREZ-SORIANO A, Arena JE, Dinelle K, Miao Q, et al
    PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27029.
    PubMed     Text format     Abstract available


  183. AKRAM H, Wu C, Hyam J, Foltynie T, et al
    l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.
    Mov Disord. 2017;32:874-883.
    PubMed     Text format     Abstract available


  184. VAILLANCOURT DE
    What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease.
    Mov Disord. 2017;32:805-806.
    PubMed     Text format    


  185. LENKA A, Pal PK
    "Miro" in Parkinson's disease: Here, there, everywhere!
    Mov Disord. 2017;32:839.
    PubMed     Text format    


    May 2017
  186. NG ASL, Tan EK
    Linking statins and lipids in Parkinson's disease.
    Mov Disord. 2017 May 27. doi: 10.1002/mds.27053.
    PubMed     Text format    


  187. DELGADO-ALVARADO M, Gago B, Gorostidi A, Jimenez-Urbieta H, et al
    Tau/alpha-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27001.
    PubMed     Text format     Abstract available


  188. KIM YJ, Jeon J, Shin J, Kim NY, et al
    Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27019.
    PubMed     Text format     Abstract available


  189. COLLIER TJ, Kanaan NM, Kordower JH
    Aging and Parkinson's disease: Different sides of the same coin?
    Mov Disord. 2017 May 18. doi: 10.1002/mds.27037.
    PubMed     Text format     Abstract available


  190. PILOTTO A, Heinzel S, Suenkel U, Lerche S, et al
    Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
    Mov Disord. 2017 May 16. doi: 10.1002/mds.27035.
    PubMed     Text format     Abstract available


  191. SHAHMOON S, Jahanshahi M
    Optimizing psychosocial adjustment after deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Mov Disord. 2017 May 15. doi: 10.1002/mds.27032.
    PubMed     Text format    


  192. YADAV AP, Nicolelis MAL
    Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.
    Mov Disord. 2017 May 12. doi: 10.1002/mds.27033.
    PubMed     Text format     Abstract available


  193. MEROLA A, Rosso M, Romagnolo A, Comi C, et al
    Peripheral neuropathy as marker of severe Parkinson's disease phenotype.
    Mov Disord. 2017 May 8. doi: 10.1002/mds.27025.
    PubMed     Text format    


  194. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.
    Mov Disord. 2017;32:724-725.
    PubMed     Text format    


  195. POSTUMA RB
    Sleep Disorders and RBD: What Would James Parkinson Think?
    Mov Disord. 2017;32:705-707.
    PubMed     Text format    


  196. ST LOUIS EK, Boeve AR, Boeve BF
    REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
    Mov Disord. 2017;32:645-658.
    PubMed     Text format     Abstract available


  197. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.
    Mov Disord. 2017;32:722-723.
    PubMed     Text format    


  198. MCKENNA D, Peever J
    Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder.
    Mov Disord. 2017;32:636-644.
    PubMed     Text format     Abstract available


  199. HOGL B, Stefani A
    Restless legs syndrome and periodic leg movements in patients with movement disorders: Specific considerations.
    Mov Disord. 2017;32:669-681.
    PubMed     Text format     Abstract available


    April 2017
  200. STROUWEN C, Molenaar EALM, Munks L, Keus SHJ, et al
    Training dual tasks together or apart in Parkinson's disease: Results from the DUALITY trial.
    Mov Disord. 2017 Apr 25. doi: 10.1002/mds.27014.
    PubMed     Text format     Abstract available


  201. DIEZ H, Cortes-Saladelafont E, Ormazabal A, Marmiese AF, et al
    Severe infantile parkinsonism because of a de novo mutation on DLP1 mitochondrial-peroxisomal protein.
    Mov Disord. 2017 Apr 24. doi: 10.1002/mds.27021.
    PubMed     Text format    


  202. OLSZEWSKA DA, Lynch T
    Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
    Mov Disord. 2017 Apr 22. doi: 10.1002/mds.27015.
    PubMed     Text format    


  203. BEAULIEU ML, Muller MLTM, Bohnen NI
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26994.
    PubMed     Text format    


  204. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.27009.
    PubMed     Text format    


  205. FERESHTEHNEJAD SM, Montplaisir JY, Pelletier A, Gagnon JF, et al
    Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26989.
    PubMed     Text format     Abstract available


  206. BURTE F, Houghton D, Lowes H, Pyle A, et al
    metabolic profiling of Parkinson's disease and mild cognitive impairment.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26992.
    PubMed     Text format     Abstract available


  207. KOOLE M, Laere KV, Ahmad R, Ceccarini J, et al
    Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.27005.
    PubMed     Text format    


  208. CACACE F, Mineo D, Viscomi MT, Latagliata EC, et al
    Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26982.
    PubMed     Text format     Abstract available


  209. YANG X, An R, Xi J, Zheng J, et al
    Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26996.
    PubMed     Text format    


  210. OLANOW CW, Kieburtz K, Leinonen M, Elmer L, et al
    A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26941.
    PubMed     Text format     Abstract available


  211. LIU G, Sterling NW, Kong L, Lewis MM, et al
    Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.27006.
    PubMed     Text format     Abstract available


  212. KORDOWER JH
    What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Mov Disord. 2017;32:483-484.
    PubMed     Text format    


  213. BALCK A, Klein C
    Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection.
    Mov Disord. 2017;32:527.
    PubMed     Text format    


    March 2017
  214. ORGAZ L, Gil GB
    Modulating mitochondrial pyruvate carrier: A promising therapeutic target in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26962.
    PubMed     Text format    


  215. FOX SH, Metman LV, Nutt JG, Brodsky M, et al
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976.
    PubMed     Text format     Abstract available


  216. PONT-SUNYER C, Tolosa E, Caspell-Garcia C, Coffey C, et al
    The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26964.
    PubMed     Text format     Abstract available


  217. LEHERICY S, Vaillancourt DE, Seppi K, Monchi O, et al
    The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26968.
    PubMed     Text format     Abstract available


  218. BARICHELLA M, Cereda E, Cassani E, Frazzitta G, et al
    A focus on Rome III criteria for the assessment of constipation in Parkinson's disease.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26974.
    PubMed     Text format    


  219. XU T, Wang S, Lalchandani RR, Ding JB, et al
    Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26938.
    PubMed     Text format     Abstract available


  220. MEROLA A, Romagnolo A, Comi C, Rosso M, et al
    Prevalence and burden of dysautonomia in advanced Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26970.
    PubMed     Text format    


  221. F HERNANDEZ L, Castela I, Ruiz-DeDiego I, Obeso JA, et al
    Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26947.
    PubMed     Text format     Abstract available


  222. ANDERKOVA L, Barton M, Rektorova I
    Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26956.
    PubMed     Text format     Abstract available


  223. PAGANO G, Niccolini F, Yousaf T, Wilson H, et al
    Urinary dysfunction in early de novo patients with Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26967.
    PubMed     Text format    


  224. PEREZ XA, Zhang D, Bordia T, Quik M, et al
    Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26955.
    PubMed     Text format     Abstract available


  225. HANSEN AK, Damholdt MF, Fedorova TD, Knudsen K, et al
    In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26961.
    PubMed     Text format     Abstract available


  226. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Text format     Abstract available


  227. MARRAS C
    What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.
    Mov Disord. 2017;32:364-365.
    PubMed     Text format    


    February 2017
  228. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Text format     Abstract available


  229. HORVATH K, Aschermann Z, Kovacs M, Makkos A, et al
    Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.
    Mov Disord. 2017 Feb 20. doi: 10.1002/mds.26960.
    PubMed     Text format     Abstract available


  230. MIKI Y, Yoshizawa T, Morohashi S, Seino Y, et al
    Neuropathology of PARK14 is identical to idiopathic Parkinson's disease.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26952.
    PubMed     Text format    


  231. ROSA M, Arlotti M, Marceglia S, Cogiamanian F, et al
    Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26953.
    PubMed     Text format    


  232. HILL-BURNS EM, Debelius JW, Morton JT, Wissemann WT, et al
    Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Mov Disord. 2017 Feb 14. doi: 10.1002/mds.26942.
    PubMed     Text format     Abstract available


  233. PONZO V, Di Lorenzo F, Brusa L, Schirinzi T, et al
    Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26931.
    PubMed     Text format     Abstract available


  234. ANSARI M, Sobhani S
    Impaired glutamate release in GPe astrocytes, disinhibits striatopallidal transmission in Parkinsonian mice.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26943.
    PubMed     Text format    


  235. GALLEA C, Ewenczyk C, Degos B, Welter ML, et al
    Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders.
    Mov Disord. 2017 Feb 6. doi: 10.1002/mds.26923.
    PubMed     Text format     Abstract available


  236. DEL REY NL, Blesa J
    Parkinson's disease: Oh my gut!
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26933.
    PubMed     Text format    


  237. MAHLKNECHT P, Krismer F, Poewe W, Seppi K, et al
    Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26932.
    PubMed     Text format     Abstract available


  238. MOLLER L, Kassubek J, Sudmeyer M, Hilker R, et al
    Manual MRI morphometry in Parkinsonian syndromes.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26921.
    PubMed     Text format     Abstract available


  239. STRAFELLA AP, Bohnen NI, Perlmutter JS, Eidelberg D, et al
    Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26907.
    PubMed     Text format     Abstract available


  240. OLANOW CW, Kordower JH
    Targeting alpha-Synuclein as a therapy for Parkinson's disease: The battle begins.
    Mov Disord. 2017;32:203-207.
    PubMed     Text format    


  241. ALBIN RL
    What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease.
    Mov Disord. 2017;32:179-180.
    PubMed     Text format    


  242. EBRAHIMI R, Sobhani S, Abbastabar M
    Whether the dissociation between toxicity and alpha-synuclein inclusion will be a possible therapy for Parkinson's disease or not?
    Mov Disord. 2017;32:210.
    PubMed     Text format    



  243. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed     Text format    


    January 2017
  244. MORBERG BM, Malling AS, Jensen BR, Gredal O, et al
    Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26927.
    PubMed     Text format    


  245. VIDENOVIC A
    Management of sleep disorders in Parkinson's disease and multiple system atrophy.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26918.
    PubMed     Text format     Abstract available


  246. NOYCE AJ, R'Bibo L, Peress L, Bestwick JP, et al
    PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26898.
    PubMed     Text format     Abstract available


  247. QUADRI M, Breedveld GJ, Chang HC, Yeh TH, et al
    Mutations in TMEM230 are not a common cause of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26900.
    PubMed     Text format    


  248. MOHASEL S, Sobhani S
    The role of amyloidogenic proteins as a meeting point of type 2 diabetes and Parkinson's disease pathways.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26897.
    PubMed     Text format    


  249. VISANJI NP, Bhudhikanok GS, Mestre TA, Ghate T, et al
    Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26896.
    PubMed     Text format     Abstract available


  250. SCHNEIDER SA, Bras J
    Mouse models of kufor-rakeb disease link Parkinson's disease closer to neuronal ceroid lipofuscinosis, suggesting lysosomal dysfunction as shared mechanism.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26899.
    PubMed     Text format    


  251. BESTE C, Muckschel M, Rosales R, Domingo A, et al
    Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.
    Mov Disord. 2017 Jan 6. doi: 10.1002/mds.26895.
    PubMed     Text format     Abstract available


  252. SPATARO N, Roca-Umbert A, Cervera-Carles L, Valles M, et al
    Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.
    Mov Disord. 2017;32:165-169.
    PubMed     Text format     Abstract available


  253. ZHANG M, Xi Z, Misquitta K, Sato C, et al
    C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism.
    Mov Disord. 2017;32:158-162.
    PubMed     Text format     Abstract available


  254. HARIZ M, Obeso JA
    What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease.
    Mov Disord. 2017;32:2-4.
    PubMed     Text format    


  255. BLUMENFELD Z, Koop MM, Prieto TE, Shreve LA, et al
    Sixty-hertz stimulation improves bradykinesia and amplifies subthalamic low-frequency oscillations.
    Mov Disord. 2017;32:80-88.
    PubMed     Text format     Abstract available


  256. CHO H, Choi JY, Hwang MS, Lee SH, et al
    Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy.
    Mov Disord. 2017;32:134-140.
    PubMed     Text format     Abstract available


  257. VALSKY D, Marmor-Levin O, Deffains M, Eitan R, et al
    Stop! border ahead: Automatic detection of subthalamic exit during deep brain stimulation surgery.
    Mov Disord. 2017;32:70-79.
    PubMed     Text format     Abstract available


    December 2016
  258. LANGLEY J, Huddleston DE, Sedlacik J, Boelmans K, et al
    Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26883.
    PubMed     Text format     Abstract available


  259. RAHMANI F, Kamalian A, Aarabi MH
    New evidence comes to light: How is alpha-synuclein aggregation related to mitochondrial protein import in Parkinson's disease?
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26889.
    PubMed     Text format    


  260. BLAUWENDRAAT C, Nalls MA, Federoff M, Pletnikova O, et al
    ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26886.
    PubMed     Text format    


  261. SENEK M, Nielsen EI, Nyholm D
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26855.
    PubMed     Text format     Abstract available


  262. PAL GD, Ouyang B, Serrano G, Shill HA, et al
    Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26882.
    PubMed     Text format     Abstract available


  263. DZAMKO N, Gysbers AM, Bandopadhyay R, Bolliger MF, et al
    LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26892.
    PubMed     Text format     Abstract available


  264. MARTINEZ-MARTIN P
    What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26885.
    PubMed     Text format     Abstract available


  265. GOETZ CG, Liu Y, Stebbins GT, Wang L, et al
    Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Mov Disord. 2016;31:1865-1873.
    PubMed     Text format     Abstract available


  266. WILLIS AW, Thibault DP, Schmidt PN, Dorsey ER, et al
    Hospital care for mental health and substance abuse conditions in Parkinson's disease.
    Mov Disord. 2016;31:1810-1819.
    PubMed     Text format     Abstract available


  267. SHI CH, Zhang SY, Yang ZH, Yang J, et al
    A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.
    Mov Disord. 2016;31:1905-1909.
    PubMed     Text format     Abstract available


    November 2016
  268. DE PABLO-FERNANDEZ E, Courtney R, Holton JL, Warner TT, et al
    Hypothalamic alpha-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease.
    Mov Disord. 2016 Nov 28. doi: 10.1002/mds.26868.
    PubMed     Text format    


  269. KNUDSEN K, Krogh K, Ostergaard K, Borghammer P, et al
    Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26866.
    PubMed     Text format     Abstract available


  270. PILLAS M, Selai C, Schrag A
    Rasch analysis of the carers quality of life questionnaire for parkinsonism.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26877.
    PubMed     Text format     Abstract available


  271. RAUSCHENDORF MA, Jost M, Stock F, Zimmer A, et al
    Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26876.
    PubMed     Text format    


  272. HE YC, Huang P, Li QQ, Sun Q, et al
    TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26875.
    PubMed     Text format    


  273. POLITIS M, Sauerbier A, Loane C, Pavese N, et al
    Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Mov Disord. 2016 Nov 17. doi: 10.1002/mds.26848.
    PubMed     Text format     Abstract available


  274. GALIMBERTI D, Cioffi SM, Fenoglio C, Serpente M, et al
    Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872.
    PubMed     Text format    


  275. FIFEL K
    Alterations of the circadian system in Parkinson's disease patients.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26865.
    PubMed     Text format     Abstract available


  276. ISOTALO J, Vahlberg T, Kaasinen V
    Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26862.
    PubMed     Text format    


  277. XIE T, Kang UJ
    Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26861.
    PubMed     Text format    


  278. GAARE JJ, Skeie GO, Tzoulis C, Larsen JP, et al
    Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.
    PubMed     Text format     Abstract available


  279. PINTO DE SOUZA C, Hamani C, Oliveira Souza C, Lopez Contreras WO, et al
    Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26850.
    PubMed     Text format     Abstract available


  280. KLETTNER A, Tholey A, Wiegandt A, Richert E, et al
    Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26863.
    PubMed     Text format     Abstract available


  281. BEUDEL M, Oswal A, Jha A, Foltynie T, et al
    Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26860.
    PubMed     Text format    


  282. DI BIASE L, Fasano A
    Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?"
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26859.
    PubMed     Text format    


  283. NEUMANN WJ, Kuhn AA
    Subthalamic beta power-Unified Parkinson's disease rating scale III correlations require akinetic symptoms.
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26858.
    PubMed     Text format    


  284. SGAMBATO-FAURE V
    Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms.
    Mov Disord. 2016 Nov 2. doi: 10.1002/mds.26840.
    PubMed     Text format    


    October 2016
  285. FOO JN, Lee J, Tan LC, Liu J, et al
    Large 3-Mb deletions at 22q11.2 locus in parkinson's disease and schizophrenia.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26822.
    PubMed     Text format    


  286. HUGHES KC, Gao X, Kim IY, Rimm EB, et al
    Intake of antioxidant vitamins and risk of parkinson's disease.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26819.
    PubMed     Text format     Abstract available


  287. TINAZZI M, Geroin C, Gandolfi M, Smania N, et al
    Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26829.
    PubMed     Text format     Abstract available


  288. MANGESIUS S, Krismer F, Gizewski ER, Muller C, et al
    1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26823.
    PubMed     Text format    


  289. SAVICA R, Grossardt BR, Bower JH, Ahlskog JE, et al
    Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26839.
    PubMed     Text format     Abstract available


  290. TARSY D
    Addition of a virtual reality component to treadmill training to reduce fall risk in older adults, including individuals with Parkinson's disease.
    Mov Disord. 2016 Oct 19. doi: 10.1002/mds.26843.
    PubMed     Text format    


  291. KHODADADI H, Azcona LJ, Aghamollaii V, Omrani MD, et al
    PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26824.
    PubMed     Text format     Abstract available


  292. TROSTER AI, Jankovic J, Tagliati M, Peichel D, et al
    Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26827.
    PubMed     Text format     Abstract available


  293. PYLE A, Lowes H, Brennan R, Kurzawa-Akanbi M, et al
    Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26825.
    PubMed     Text format    


  294. BALINT B, Bhatia KP
    SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia.
    Mov Disord. 2016 Oct 14. doi: 10.1002/mds.26821.
    PubMed     Text format    


  295. KLEIN C, Lochte T, Delamonte SM, Braenne I, et al
    PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical Features and Neuropathology.
    Mov Disord. 2016 Oct 6. doi: 10.1002/mds.26814.
    PubMed     Text format    


  296. POLLI A, Weis L, Biundo R, Thacker M, et al
    Anatomical and functional correlates of persistent pain in parkinson's disease.
    Mov Disord. 2016 Oct 5. doi: 10.1002/mds.26826.
    PubMed     Text format     Abstract available


    September 2016
  297. PONS R, Kekou K, Antonellou R, Svingou M, et al
    Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease.
    Mov Disord. 2016 Sep 26. doi: 10.1002/mds.26807.
    PubMed     Text format    


  298. SVENSSON E, Horvath-Puho E, Stokholm MG, Sorensen HT, et al
    Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26761.
    PubMed     Text format     Abstract available


  299. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naive cohort.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26742.
    PubMed     Text format     Abstract available


  300. WONG YC, Krainc D
    Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26802.
    PubMed     Text format     Abstract available


  301. KETT LR, Dauer WT
    Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26797.
    PubMed     Text format     Abstract available


  302. RIEDEL O
    Bringing light into the darkness: Dependence in Parkinson's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26795.
    PubMed     Text format    


  303. DELVAL A, Rambour M, Tard C, Dujardin K, et al
    Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26762.
    PubMed     Text format     Abstract available


    August 2016
  304. KIM JM, Jang ES, Ok K, Oh ES, et al
    Association between hepatitis C virus infection and Parkinson's disease.
    Mov Disord. 2016 Aug 23. doi: 10.1002/mds.26755.
    PubMed     Text format    


  305. MAJBOUR NK, Vaikath NN, Eusebi P, Chiasserini D, et al
    Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26754.
    PubMed     Text format     Abstract available


  306. ONDER H
    Dominant-side onset in Parkinson's disease and better motor performance?
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26752.
    PubMed     Text format    


  307. MACLEOD AD, Counsell CE
    Predictors of functional dependency in Parkinson's disease.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26751.
    PubMed     Text format     Abstract available


  308. SOHN YH, Ham JH
    Dominant-side onset in Parkinson's disease and better motor performance?
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26750.
    PubMed     Text format    


  309. NEUMANN WJ, Degen K, Schneider GH, Brucke C, et al
    Subthalamic synchronized oscillatory activity correlates with motor impairment in patients with Parkinson's disease.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26759.
    PubMed     Text format     Abstract available


  310. FIGGE DA, Standaert DG
    SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26747.
    PubMed     Text format    


  311. DORSEY ER, Vlaanderen FP, Engelen LJ, Kieburtz K, et al
    Moving Parkinson care to the home.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26744.
    PubMed     Text format     Abstract available


  312. VARANDA S, Ribeiro da Silva J, Costa AS, Amorim de Carvalho C, et al
    Sexual dysfunction in women with Parkinson's disease.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26739.
    PubMed     Text format     Abstract available


  313. KUBOTA KJ, Chen JA, Little MA
    Machine learning for large-scale wearable sensor data in Parkinson's disease: Concepts, promises, pitfalls, and futures.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26693.
    PubMed     Text format     Abstract available


  314. SANCHEZ-FERRO A, Maetzler W
    Advances in sensor and wearable technologies for Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26746.
    PubMed     Text format    


  315. PIFL C
    Problems with traffic ahead: Synaptic vesicles in Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26735.
    PubMed     Text format    


  316. LAHUE SC, Comella CL, Tanner CM
    The best medicine? The influence of physical activity and inactivity on Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26728.
    PubMed     Text format     Abstract available


  317. DAMS J, Balzer-Geldsetzer M, Siebert U, Deuschl G, et al
    Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
    Mov Disord. 2016;31:1183-91.
    PubMed     Text format     Abstract available


    July 2016
  318. KRISMER F, Seppi K, Wenning GK, Abler V, et al
    Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.
    Mov Disord. 2016 Jul 30. doi: 10.1002/mds.26743.
    PubMed     Text format     Abstract available


  319. WESSEL JR, Ghahremani A, Udupa K, Saha U, et al
    Stop-related subthalamic beta activity indexes global motor suppression in Parkinson's disease.
    Mov Disord. 2016 Jul 30. doi: 10.1002/mds.26732.
    PubMed     Text format     Abstract available


  320. BERMAN BD, Smucny J, Wylie KP, Shelton E, et al
    Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease.
    Mov Disord. 2016 Jul 27. doi: 10.1002/mds.26713.
    PubMed     Text format     Abstract available


  321. DEL DIN S, Godfrey A, Mazza C, Lord S, et al
    Free-living monitoring of Parkinson's disease: Lessons from the field.
    Mov Disord. 2016 Jul 25. doi: 10.1002/mds.26718.
    PubMed     Text format     Abstract available


  322. HUPPERTZ HJ, Moller L, Sudmeyer M, Hilker R, et al
    Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification.
    Mov Disord. 2016 Jul 25. doi: 10.1002/mds.26715.
    PubMed     Text format     Abstract available


  323. SVENNINGSSON P, Wirdefeldt K, Yin L, Fang F, et al
    Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26734.
    PubMed     Text format    


  324. MARTINEZ-FERNANDEZ R, Schmitt E, Martinez-Martin P, Krack P, et al
    The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26731.
    PubMed     Text format     Abstract available


  325. RASCOL O, Hauser RA, Stocchi F, Fitzer-Attas CJ, et al
    Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26724.
    PubMed     Text format     Abstract available


  326. SANCHEZ-FERRO A, Elshehabi M, Godinho C, Salkovic D, et al
    New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26723.
    PubMed     Text format     Abstract available


  327. MIRELMAN A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, et al
    Arm swing as a potential new prodromal marker of Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26720.
    PubMed     Text format     Abstract available


  328. NONNEKES J, Timmer MH, de Vries NM, Rascol O, et al
    Unmasking levodopa resistance in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26712.
    PubMed     Text format     Abstract available


  329. SANKAR T, Li SX, Obuchi T, Fasano A, et al
    Structural brain changes following subthalamic nucleus deep brain stimulation in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26707.
    PubMed     Text format    


  330. HAUSER RA, Olanow CW, Dzyngel B, Bilbault T, et al
    Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26697.
    PubMed     Text format     Abstract available


  331. LOEFFLER DA, LeWitt PA, Camp DM
    Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?
    Mov Disord. 2016 Jul 14. doi: 10.1002/mds.26711.
    PubMed     Text format    


  332. MESTRE TA, Sidiropoulos C, Hamani C, Poon YY, et al
    Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease.
    Mov Disord. 2016 Jul 9. doi: 10.1002/mds.26710.
    PubMed     Text format     Abstract available



  333. Retraction: 'Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial,' by Sato, Y., Iwamoto, J., Kanoko, T., and Satoh, K.
    Mov Disord. 2016;31:1077.
    PubMed     Text format     Abstract available


    June 2016
  334. ANTUNES L, Frasquilho S, Ostaszewski M, Weber J, et al
    Similar alpha-Synuclein staining in the colon mucosa in patients with Parkinson's disease and controls.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26702.
    PubMed     Text format     Abstract available


  335. DAMS J, Dodel R
    An economic evaluation of deep brain stimulation for patients with Parkinson's disease.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26701.
    PubMed     Text format    


  336. MALEK N, Lawton MA, Swallow DM, Grosset KA, et al
    Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26698.
    PubMed     Text format     Abstract available


  337. FRASER KB, Rawlins AB, Clark RG, Alcalay RN, et al
    Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.
    Mov Disord. 2016 Jun 14. doi: 10.1002/mds.26686.
    PubMed     Text format     Abstract available


  338. ROSSI M, Escobar AM, Bril A, Millar Vernetti P, et al
    Motor features in Parkinson's disease with normal olfactory function.
    Mov Disord. 2016 Jun 9. doi: 10.1002/mds.26687.
    PubMed     Text format     Abstract available


  339. MAETZLER W, Klucken J, Horne M
    A clinical view on the development of technology-based tools in managing Parkinson's disease.
    Mov Disord. 2016 Jun 7. doi: 10.1002/mds.26673.
    PubMed     Text format     Abstract available


  340. MAHLKNECHT P, Gasperi A, Willeit P, Kiechl S, et al
    Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26674.
    PubMed     Text format     Abstract available


  341. COTELLI M, Manenti R, Brambilla M, Borroni B, et al
    Reply to letter to the editor "tDCS effect on cognitive performance in Parkinson's disease" by Biundo et al.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26684.
    PubMed     Text format    


  342. NAKAMURA T, Suzuki M, Okada A, Suzuki J, et al
    Association of leptin with orthostatic blood pressure changes in Parkinson's disease.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26678.
    PubMed     Text format     Abstract available


  343. BIUNDO R, Weis L, Antonini A
    tDCS effect on cognitive performance in Parkinson's disease.
    Mov Disord. 2016 Jun 2. doi: 10.1002/mds.26685.
    PubMed     Text format    


  344. CALABRESI P, Standaert DG, Chiasserini D, Parnetti L, et al
    Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.
    Mov Disord. 2016;31:769-70.
    PubMed     Text format    



  345. Abstracts of the Twentieth International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2016;31 Suppl 2:S1-S802.
    PubMed     Text format    


    May 2016
  346. VAN UEM JM, Maier KS, Hucker S, Scheck O, et al
    Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life.
    Mov Disord. 2016 May 31. doi: 10.1002/mds.26676.
    PubMed     Text format    


  347. MARRAS C, Lang AE, Austin PC, Lau C, et al
    Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study.
    Mov Disord. 2016 May 31. doi: 10.1002/mds.26670.
    PubMed     Text format     Abstract available


  348. NUTT JG
    Motor subtype in Parkinson's disease: Different disorders or different stages of disease?
    Mov Disord. 2016 May 26. doi: 10.1002/mds.26657.
    PubMed     Text format    


  349. VENUTO CS, Potter NB, Ray Dorsey E, Kieburtz K, et al
    A review of disease progression models of Parkinson's disease and applications in clinical trials.
    Mov Disord. 2016 May 26. doi: 10.1002/mds.26644.
    PubMed     Text format     Abstract available


  350. HIRSCHMANN J, Butz M, Hartmann CJ, Hoogenboom N, et al
    Parkinsonian Rest Tremor Is Associated With Modulations of Subthalamic High-Frequency Oscillations.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26663.
    PubMed     Text format     Abstract available


  351. TISON F, Keywood C, Wakefield M, Durif F, et al
    A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26659.
    PubMed     Text format     Abstract available


  352. TRENKWALDER C, Stocchi F, Poewe W, Dronamraju N, et al
    Mavoglurant in Parkinson's Patients With l-Dopa-Induced Dyskinesias: Two Randomized Phase 2 Studies.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26585.
    PubMed     Text format     Abstract available


  353. SCHREGLMANN SR, Houlden H
    VPS13C-Another Hint at Mitochondrial Dysfunction in Familial Parkinson's Disease.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26682.
    PubMed     Text format    


  354. DELGADO-ALVARADO M, Gago B, Navalpotro-Gomez I, Jimenez-Urbieta H, et al
    Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26662.
    PubMed     Text format     Abstract available


  355. SHULMAN LM, Armstrong M, Ellis T, Gruber-Baldini A, et al
    Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26649.
    PubMed     Text format     Abstract available


  356. SCHIRINZI T, Madeo G, Martella G, Maltese M, et al
    Early synaptic dysfunction in Parkinson's disease: Insights from animal models.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26620.
    PubMed     Text format     Abstract available


  357. DI BIASE L, Fasano A
    Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?
    Mov Disord. 2016 May 13. doi: 10.1002/mds.26658.
    PubMed     Text format     Abstract available


  358. MAHLKNECHT P, Pechlaner R, Boesveldt S, Volc D, et al
    Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease.
    Mov Disord. 2016 May 9. doi: 10.1002/mds.26637.
    PubMed     Text format     Abstract available


  359. BLENNOW K, Biscetti L, Eusebi P, Parnetti L, et al
    Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.
    Mov Disord. 2016 May 4. doi: 10.1002/mds.26656.
    PubMed     Text format     Abstract available


  360. TESSITORE A, Giordano A, De Micco R, Caiazzo G, et al
    Functional connectivity underpinnings of fatigue in "Drug-Naive" patients with Parkinson's disease.
    Mov Disord. 2016 May 4. doi: 10.1002/mds.26650.
    PubMed     Text format     Abstract available


  361. HALBGEBAUER S, Ockl P, Wirth K, Steinacker P, et al
    Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins.
    Mov Disord. 2016 May 2. doi: 10.1002/mds.26635.
    PubMed     Text format     Abstract available


  362. JABERI E, Rohani M, Shahidi GA, Nafissi S, et al
    Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.
    Mov Disord. 2016 May 2. doi: 10.1002/mds.26627.
    PubMed     Text format     Abstract available


  363. YARNALL AJ, Lashley T, Ling H, Lees AJ, et al
    Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?
    Mov Disord. 2016;31:668-75.
    PubMed     Text format     Abstract available


    April 2016
  364. OLSZEWSKA DA, Lynch T
    MUL1-A new potential for a therapeutic target for Parkinson's disease a commentary on "MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin" by Yun and colleagues (eLife 2014; 3: 1-26).
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26652.
    PubMed     Text format    


  365. BROEN MP, Narayen NE, Kuijf ML, Dissanayaka NN, et al
    Prevalence of anxiety in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26643.
    PubMed     Text format     Abstract available


  366. ESPAY AJ, Bonato P, Nahab FB, Maetzler W, et al
    Technology in Parkinson's disease: Challenges and opportunities.
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26642.
    PubMed     Text format     Abstract available


  367. KANG UJ, Goldman JG, Alcalay RN, Xie T, et al
    The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Mov Disord. 2016 Apr 26. doi: 10.1002/mds.26613.
    PubMed     Text format     Abstract available


  368. LOANE C, Politis M, Kefalopoulou Z, Valle-Guzman N, et al
    Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study.
    Mov Disord. 2016 Apr 22. doi: 10.1002/mds.26606.
    PubMed     Text format     Abstract available


  369. URIBE C, Segura B, Baggio HC, Abos A, et al
    Patterns of Cortical Thinning in Nondemented Parkinson's Disease Patients.
    Mov Disord. 2016 Apr 20. doi: 10.1002/mds.26590.
    PubMed     Text format     Abstract available


  370. ROSS GW, Petrovitch H, Abbott RD
    Serum vitamin D and risk of Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26639.
    PubMed     Text format    


  371. MCDONALD C, Newton JL, Burn DJ
    Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26632.
    PubMed     Text format     Abstract available


  372. ZHANG J, Nombela C, Wolpe N, Barker RA, et al
    Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26631.
    PubMed     Text format     Abstract available


  373. SCHAPIRA AH, Chiasserini D, Beccari T, Parnetti L, et al
    Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26616.
    PubMed     Text format     Abstract available


  374. MARRAS C, Alcalay RN, Caspell-Garcia C, Coffey C, et al
    Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26614.
    PubMed     Text format     Abstract available


  375. LEWITT PA, Hauser RA, Grosset DG, Stocchi F, et al
    A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26611.
    PubMed     Text format     Abstract available


  376. SHRESTHA S, Lutsey PL, Alonso A, Huang X, et al
    Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26573.
    PubMed     Text format     Abstract available


  377. CAVINESS JN, Lue LF, Hentz JG, Schmitz CT, et al
    Cortical phosphorylated alpha-Synuclein levels correlate with brain wave spectra in Parkinson's disease.
    Mov Disord. 2016 Apr 8. doi: 10.1002/mds.26621.
    PubMed     Text format     Abstract available


  378. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.
    Mov Disord. 2016;31:436-57.
    PubMed     Text format     Abstract available


  379. GREENE P
    Are more effective placebos complicating clinical trials?
    Mov Disord. 2016;31:606.
    PubMed     Text format    


  380. WEISS D, Herrmann S, Wang L, Schulte C, et al
    Alpha-synuclein gene variants may predict neurostimulation outcome.
    Mov Disord. 2016;31:601-3.
    PubMed     Text format    


  381. LAWTON M, Kasten M, May MT, Mollenhauer B, et al
    Validation of conversion between mini-mental state examination and montreal cognitive assessment.
    Mov Disord. 2016;31:593-6.
    PubMed     Text format     Abstract available


  382. LANG AE, Rodriguez RL, Boyd JT, Chouinard S, et al
    Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Mov Disord. 2016;31:538-46.
    PubMed     Text format     Abstract available


    March 2016
  383. FORLONI G, Artuso V, La Vitola P, Balducci C, et al
    Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26624.
    PubMed     Text format     Abstract available


  384. WEINTRAUB D, Hauser RA, Elm JJ, Pagan F, et al
    Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26617.
    PubMed     Text format     Abstract available


  385. ADLER CH, Beach TG
    Neuropathological basis of nonmotor manifestations of Parkinson's disease.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26605.
    PubMed     Text format     Abstract available


  386. COPELAND JN, Lieberman A, Oravivattanakul S, Troster AI, et al
    Accuracy of Patient and Care Partner Identification of Cognitive Impairments in Parkinson's Disease-Mild Cognitive Impairment.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26619.
    PubMed     Text format     Abstract available


  387. KLUGER BM, Rakowski D, Christian M, Cedar D, et al
    Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26597.
    PubMed     Text format     Abstract available


  388. DE GERMAY S, Montastruc JL, Rousseau V, Chebane L, et al
    Atropinic (Anticholinergic) Burden in Parkinson's Disease.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26595.
    PubMed     Text format     Abstract available


  389. WILLIAMS-GRAY CH, Wijeyekoon R, Yarnall AJ, Lawson RA, et al
    Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
    Mov Disord. 2016 Mar 21. doi: 10.1002/mds.26563.
    PubMed     Text format     Abstract available


  390. FLORES-CUADRADO A, Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C, et al
    Hippocampal alpha-synuclein and interneurons in Parkinson's disease: Data from human and mouse models.
    Mov Disord. 2016 Mar 18. doi: 10.1002/mds.26586.
    PubMed     Text format     Abstract available


  391. BAE YJ, Kim JM, Kim E, Lee KM, et al
    Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With I-FP-CIT SPECT.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26584.
    PubMed     Text format     Abstract available


  392. QUADRI M, Olgiati S, Sensi M, Gualandi F, et al
    PRKRA Mutation Causing Early-Onset Generalized Dystonia-Parkinsonism (DYT16) in an Italian Family.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26583.
    PubMed     Text format    


  393. NACKAERTS E, Heremans E, Vervoort G, Smits-Engelsman BC, et al
    Relearning of Writing Skills in Parkinson's Disease After Intensive Amplitude Training.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26565.
    PubMed     Text format     Abstract available


  394. BREEN DP, Nombela C, Vuono R, Jones PS, et al
    Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease.
    Mov Disord. 2016 Mar 12. doi: 10.1002/mds.26592.
    PubMed     Text format     Abstract available


  395. TAN B, Double KL, Burne J, Diong J, et al
    Tension-referenced measures of gastrocnemius slack length and stiffness in Parkinson's disease.
    Mov Disord. 2016 Mar 11. doi: 10.1002/mds.26530.
    PubMed     Text format     Abstract available


  396. HERZ DM, Haagensen BN, Nielsen SH, Madsen KH, et al
    Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Mov Disord. 2016 Mar 8. doi: 10.1002/mds.26540.
    PubMed     Text format     Abstract available


  397. VICENTE MIRANDA H, El-Agnaf OM, Outeiro TF
    Glycation in Parkinson's disease and Alzheimer's disease.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26566.
    PubMed     Text format     Abstract available


  398. RICCIARDI L, Bove F, Espay KJ, Lena F, et al
    24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26564.
    PubMed     Text format    


  399. BLOEM BR, Marinus J, Almeida Q, Dibble L, et al
    Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26572.
    PubMed     Text format     Abstract available



  400. Corrigenda: Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.
    Mov Disord. 2016;31:433.
    PubMed     Text format    



  401. Abstracts of the Fifth Asian and Oceanian Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2016;31 Suppl 1:S1-S103.
    PubMed     Text format    


  402. HERNANDEZ LF
    An A-PLAuse to a new assay that unveils previously undetected alpha-synucleinopathies.
    Mov Disord. 2016;31:301.
    PubMed     Text format    


  403. SWALLOW DM, Grosset KA, Grosset DG
    Nonmotor symptoms in patients without evidence of dopaminergic deficit.
    Mov Disord. 2016;31:429-30.
    PubMed     Text format    


  404. SPRENGER FS, Seppi K, Djamshidian A, Poewe W, et al
    Reply to "Nonmotor symptoms in subjects without evidence of dopaminergic deficit" authors: "Swallow DMA, Grosset KA, Grosset DG".
    Mov Disord. 2016;31:430-1.
    PubMed     Text format    


  405. MESTRE TA, Lang AE, Okun MS
    Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mov Disord. 2016;31:290-6.
    PubMed     Text format     Abstract available


  406. OROPESA-RUIZ JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, et al
    Low serum uric acid levels in progressive supranuclear palsy.
    Mov Disord. 2016;31:402-5.
    PubMed     Text format     Abstract available


  407. WILE DJ, Dinelle K, Vafai N, McKenzie J, et al
    A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
    Mov Disord. 2016;31:405-9.
    PubMed     Text format     Abstract available


  408. WALTER U, Muller JU, Rosche J, Kirsch M, et al
    Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location.
    Mov Disord. 2016;31:302-9.
    PubMed     Text format     Abstract available


    February 2016
  409. MOORS T, Paciotti S, Chiasserini D, Calabresi P, et al
    Lysosomal Dysfunction and alpha-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links.
    Mov Disord. 2016 Feb 29. doi: 10.1002/mds.26562.
    PubMed     Text format     Abstract available


  410. NOWINSKI CJ, Siderowf A, Simuni T, Wortman C, et al
    Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease.
    Mov Disord. 2016 Feb 26. doi: 10.1002/mds.26546.
    PubMed     Text format     Abstract available


  411. FIORENTINI C, Savoia P, Savoldi D, Bono F, et al
    Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Mov Disord. 2016 Feb 22. doi: 10.1002/mds.26581.
    PubMed     Text format     Abstract available


  412. BERG D, Postuma RB
    Diagnosis of Parkinson's disease: Imaging and genetics.
    Mov Disord. 2016 Feb 22. doi: 10.1002/mds.26544.
    PubMed     Text format    


  413. ERRO R, Bhatia KP
    Novel movement disorder society-Parkinson's disease criteria: What about SWEDD and genetic forms?
    Mov Disord. 2016 Feb 19. doi: 10.1002/mds.26538.
    PubMed     Text format    


  414. SPRENGER FS, Wurster I, Seppi K, Stockner H, et al
    Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
    Mov Disord. 2016 Feb 19. doi: 10.1002/mds.26515.
    PubMed     Text format     Abstract available


  415. NAVNTOFT CA, Dreyer JK
    How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum.
    Mov Disord. 2016 Feb 18. doi: 10.1002/mds.26579.
    PubMed     Text format     Abstract available


  416. MANENTI R, Brambilla M, Benussi A, Rosini S, et al
    Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26561.
    PubMed     Text format     Abstract available


  417. MULLER T, Kohlhepp W
    Hypomethylation in Parkinson's disease: An epigenetic drug effect?
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26560.
    PubMed     Text format    


  418. KLETTNER A, Richert E, Kuhlenbaumer G, Nolle B, et al
    Alpha synuclein and crystallin expression in human lens in Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26557.
    PubMed     Text format    


  419. CALIGIURI ME, Nistico R, Arabia G, Morelli M, et al
    Alterations of putaminal shape in de novo Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26550.
    PubMed     Text format     Abstract available


  420. ADLER CH, Hentz JG, Beach TG
    Assessing medication role on neuropathological findings in Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26536.
    PubMed     Text format    


  421. PALMA JA, Norcliffe-Kaufmann L, Kaufmann H
    An orthostatic hypotension mimic: The inebriation-like syndrome in Parkinson disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26516.
    PubMed     Text format    


  422. KLUGER BM, Herlofson K, Chou KL, Lou JS, et al
    Parkinson's disease-related fatigue: A case definition and recommendations for clinical research.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26511.
    PubMed     Text format     Abstract available


  423. HALL S, Surova Y, Ohrfelt A, Blennow K, et al
    Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26578.
    PubMed     Text format     Abstract available


  424. RANGO M, Piatti M, Di Fonzo A, Ardolino G, et al
    Abnormal brain temperature in early-onset Parkinson's disease.
    Mov Disord. 2016 Feb 13. doi: 10.1002/mds.26548.
    PubMed     Text format    


  425. DING C, Ganesvaran G, Alty JE, Clissold BG, et al
    Study of levodopa response in Parkinson's disease: Observations on rates of motor progression.
    Mov Disord. 2016 Feb 13. doi: 10.1002/mds.26497.
    PubMed     Text format     Abstract available


  426. PINNA A, Ko WK, Costa G, Tronci E, et al
    Antidyskinetic effect of A and 5HT receptor ligands in two animal models of Parkinson's disease.
    Mov Disord. 2016 Feb 12. doi: 10.1002/mds.26475.
    PubMed     Text format     Abstract available


  427. TAYLOR S, Gafton J, Shah B, Pagano G, et al
    Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism.
    Mov Disord. 2016 Feb 11. doi: 10.1002/mds.26456.
    PubMed     Text format     Abstract available


  428. SOMEKO H, Hanajima R, Tsutsumi R, Tominaga N, et al
    Abnormal myocardial scintigraphy in a GTP cyclohydrolase 1 mutation carrier with Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26523.
    PubMed     Text format    


  429. MARRAS C, Chaudhuri KR
    Nonmotor features of Parkinson's disease subtypes.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26510.
    PubMed     Text format     Abstract available


  430. CASTELA I
    GABA: Inhibition brings new excitement in Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26507.
    PubMed     Text format    


  431. MOELTER ST, Weintraub D, Mace L, Cary M, et al
    Research consent capacity varies with executive function and memory in Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26469.
    PubMed     Text format     Abstract available


  432. CARR J, Guella I, Szu-Tu C, Boolay S, et al
    Double homozygous mutations (R275W and M432V) in the ParkinGene associated with late-onset Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26524.
    PubMed     Text format    


  433. GATT AP, Duncan OF, Attems J, Francis PT, et al
    Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26513.
    PubMed     Text format     Abstract available


  434. PIHLSTROM L, Morset KR, Grimstad E, Vitelli V, et al
    A cumulative genetic risk score predicts progression in Parkinson's disease.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26505.
    PubMed     Text format     Abstract available


  435. ZHANG P, Shao XY, Qi GJ, Chen Q, et al
    Cdk5-Dependent Activation of Neuronal Inflammasomes in Parkinson's Disease.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26488.
    PubMed     Text format     Abstract available


  436. LEE JY, Yun EJ, Lee WW, Kim YK, et al
    Lateral geniculate atrophy in Parkinson's with visual hallucination: A trans-synaptic degeneration?
    Mov Disord. 2016 Feb 5. doi: 10.1002/mds.26533.
    PubMed     Text format     Abstract available


  437. MCINTOSH E, Gray A, Daniels J, Gill S, et al
    Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial.
    Mov Disord. 2016 Feb 5. doi: 10.1002/mds.26423.
    PubMed     Text format     Abstract available


  438. STEFANOVA N, Kordower JH, Wenning GK
    Preface.
    Mov Disord. 2016;31:151.
    PubMed     Text format    


  439. RICCIARDI L, Petrucci S, Di Giuda D, Serra L, et al
    The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation.
    Mov Disord. 2016;31:257-8.
    PubMed     Text format    


  440. RUFFMANN C, Parkkinen L
    Gut Feelings About alpha-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?
    Mov Disord. 2016;31:193-202.
    PubMed     Text format     Abstract available


  441. CALO L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M, et al
    Synaptic failure and alpha-synuclein.
    Mov Disord. 2016;31:169-77.
    PubMed     Text format     Abstract available


  442. BERGSTROM AL, Kallunki P, Fog K
    Development of Passive Immunotherapies for Synucleinopathies.
    Mov Disord. 2016;31:203-13.
    PubMed     Text format     Abstract available


  443. VALERA E, Masliah E
    Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Mov Disord. 2016;31:225-34.
    PubMed     Text format     Abstract available


  444. MCCANN H, Cartwright H, Halliday GM
    Neuropathology of alpha-synuclein propagation and braak hypothesis.
    Mov Disord. 2016;31:152-60.
    PubMed     Text format     Abstract available


  445. SCHNEEBERGER A, Tierney L, Mandler M
    Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Mov Disord. 2016;31:214-24.
    PubMed     Text format     Abstract available


    January 2016
  446. VIDENOVIC A, Willis GL
    Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease?
    Mov Disord. 2016 Jan 30. doi: 10.1002/mds.26509.
    PubMed     Text format     Abstract available


  447. ANTONINI A, Fung VS, Boyd JT, Slevin JT, et al
    Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Mov Disord. 2016 Jan 28. doi: 10.1002/mds.26528.
    PubMed     Text format     Abstract available


  448. MALEKMOHAMMADI M, Herron J, Velisar A, Blumenfeld Z, et al
    Kinematic Adaptive Deep Brain Stimulation for Resting Tremor in Parkinson's Disease.
    Mov Disord. 2016 Jan 27. doi: 10.1002/mds.26482.
    PubMed     Text format    


  449. XILOURI M, Brekk OR, Stefanis L
    Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Mov Disord. 2016 Jan 27. doi: 10.1002/mds.26477.
    PubMed     Text format     Abstract available


  450. BHATTACHARYYA S, Bakshi R, Logan R, Ascherio A, et al
    Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
    Mov Disord. 2016 Jan 25. doi: 10.1002/mds.26483.
    PubMed     Text format     Abstract available


  451. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings.
    Mov Disord. 2016 Jan 22. doi: 10.1002/mds.26476.
    PubMed     Text format     Abstract available


  452. CAKMAK YO
    Coffee consumption, smoking, and Parkinson's disease? The beneficial role of hydrogen sulfide.
    Mov Disord. 2016 Jan 14. doi: 10.1002/mds.26526.
    PubMed     Text format    


  453. MACEROLLO A, Chen JC, Korlipara P, Foltynie T, et al
    Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson's disease: A test of a new framework for bradykinesia.
    Mov Disord. 2016 Jan 9. doi: 10.1002/mds.26493.
    PubMed     Text format     Abstract available


  454. SAITO Y, Shioya A, Sano T, Sumikura H, et al
    Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders.
    Mov Disord. 2016 Jan 8. doi: 10.1002/mds.26463.
    PubMed     Text format     Abstract available


  455. CARTA M, Cenci MA
    On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Mov Disord. 2016;31:149.
    PubMed     Text format    


  456. OLANOW CW, Poewe W
    Eldad Melamed 1942-2015: Ave atque--A memorial.
    Mov Disord. 2016;31:39-40.
    PubMed     Text format    


    December 2015
  457. REYNOLDS GO, Otto MW, Ellis TD, Cronin-Golomb A, et al
    The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.
    Mov Disord. 2015 Dec 30. doi: 10.1002/mds.26484.
    PubMed     Text format     Abstract available


  458. NOYCE AJ, Nalls MA
    Mendelian Randomization - the Key to Understanding Aspects of Parkinson's Disease Causation?
    Mov Disord. 2015 Dec 23. doi: 10.1002/mds.26492.
    PubMed     Text format     Abstract available


  459. MARTINEZ-MARTIN P, Leentjens AF, de Pedro-Cuesta J, Chaudhuri KR, et al
    Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease.
    Mov Disord. 2015 Dec 22. doi: 10.1002/mds.26522.
    PubMed     Text format     Abstract available


  460. WILLIAMS-GRAY CH
    A new biomarker for Parkinson's disease?
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26448.
    PubMed     Text format    


  461. FOO JN, Chung SJ, Tan LC, Liany H, et al
    Linking a genome-wide association study signal to a LRRK2 coding variant in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26495.
    PubMed     Text format     Abstract available


  462. BERGARECHE A, Rodriguez-Oroz MC, Estanga A, Gorostidi A, et al
    DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26478.
    PubMed     Text format     Abstract available


  463. CHUNG SJ, Kim J, Lee HJ, Ryu HS, et al
    Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26473.
    PubMed     Text format     Abstract available


  464. BROEN MP, Kohler S, Moonen AJ, Kuijf ML, et al
    Modeling anxiety in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26461.
    PubMed     Text format     Abstract available


  465. UDUPA K, Chen R
    Role of dopamine in motor cortex plasticity in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26451.
    PubMed     Text format    


  466. BARBAGALLO G, Sierra-Pena M, Nemmi F, Traon AP, et al
    Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.
    Mov Disord. 2015 Dec 17. doi: 10.1002/mds.26471.
    PubMed     Text format     Abstract available


  467. DE VRIES NM, Nonnekes J, Bloem BR
    Toward affordable falls prevention in Parkinson's disease.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26474.
    PubMed     Text format    


  468. FRIEDMAN JH
    Editorial on: Pagonabarraga J, Martinez-Hora S, Fernandez de Bobadilla R et al. Minor hallucinations occur in drug-naive Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; Available from: DOI: 10.1002/mds.26432.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26472.
    PubMed     Text format    


  469. BOEL JA, Odekerken VJ, Geurtsen GJ, Schmand BA, et al
    Psychiatric and social outcome after deep brain stimulation for advanced Parkinson's disease.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26468.
    PubMed     Text format     Abstract available


  470. SHUAIB UA, Rajput AH, Robinson CA, Rajput A, et al
    Neuroleptic-induced Parkinsonism: Clinicopathological study.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26467.
    PubMed     Text format     Abstract available


  471. DIEDERICH NJ, Goldman JG, Stebbins GT, Goetz CG, et al
    Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease.
    Mov Disord. 2015 Dec 9. doi: 10.1002/mds.26460.
    PubMed     Text format     Abstract available


  472. HENTZ JG, Mehta SH, Shill HA, Driver-Dunckley E, et al
    Simplified conversion method for unified Parkinson's disease rating scale motor examinations.
    Mov Disord. 2015;30:1967-70.
    PubMed     Text format     Abstract available


    November 2015
  473. SWANSON CR, Alcalay RN, Chen-Plotkin A
    Reply to letter: Plasma fasting cholesterol profiles and age at onset in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26447.
    PubMed     Text format    


  474. MASTERS JM, Bestwick J, Warner TT, Giovannoni G, et al
    Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26462.
    PubMed     Text format    


  475. MAHLKNECHT P, Sprenger F, Seppi K, Poewe W, et al
    Plasma fasting cholesterol profiles and age at onset in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26452.
    PubMed     Text format    


  476. ERRO R, Barone P
    Toward the premotor diagnosis of Parkinson's disease: Suggestions from a modelling study.
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26440.
    PubMed     Text format    


  477. KOJOVIC M, Bologna M, Edwards MJ, Rothwell JC, et al
    Reply to "Transcranial Magnetic Stimulation for Parkinson's Disease".
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26441.
    PubMed     Text format    


  478. VAN DEN NOORT M, Bosch P, Yeo S, Lim S, et al
    Transcranial Magnetic Stimulation for Parkinson's Disease.
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26439.
    PubMed     Text format    


  479. NICOLETTI A, Zappia M
    Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Mov Disord. 2015;30:1854-6.
    PubMed     Text format    


  480. PAPAGIANNAKIS N, Xilouri M, Koros C, Stamelou M, et al
    Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients.
    Mov Disord. 2015;30:1830-4.
    PubMed     Text format     Abstract available


  481. LIM TT, Kluger BM, Rodriguez RL, Malaty IA, et al
    Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
    Mov Disord. 2015;30:1825-30.
    PubMed     Text format     Abstract available


  482. FUNG VS, Kordower JH
    Parkinson's disease and prion disease: Straining the comparison.
    Mov Disord. 2015;30:1727.
    PubMed     Text format    


  483. OLANOW CW, Bartus RT, Volpicelli-Daley LA, Kordower JH, et al
    Trophic factors for Parkinson's disease: To live or let die.
    Mov Disord. 2015;30:1715-24.
    PubMed     Text format     Abstract available


    October 2015
  484. SOLLA P, Fasano A, Cannas A, Marrosu F, et al
    Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease.
    Mov Disord. 2015 Oct 10. doi: 10.1002/mds.26443.
    PubMed     Text format    


  485. ROSENTHAL LS, Drake D, Alcalay RN, Babcock D, et al
    The NINDS Parkinson's disease biomarkers program.
    Mov Disord. 2015 Oct 7. doi: 10.1002/mds.26438.
    PubMed     Text format     Abstract available


  486. BERG D, Postuma RB, Adler CH, Bloem BR, et al
    MDS research criteria for prodromal Parkinson's disease.
    Mov Disord. 2015;30:1600-11.
    PubMed     Text format     Abstract available


  487. POSTUMA RB, Berg D, Stern M, Poewe W, et al
    MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2015;30:1591-601.
    PubMed     Text format     Abstract available


  488. VAN STEENOVEN I, Aarsland D, Weintraub D
    Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al.
    Mov Disord. 2015;30:1711.
    PubMed     Text format    


  489. ARMSTRONG MJ, Duff-Canning S, Psych C, Kowgier M, et al
    Independent application of montreal cognitive assessment/mini-mental state examination conversion.
    Mov Disord. 2015;30:1710-1.
    PubMed     Text format    


    September 2015
  490. PAGONABARRAGA J, Martinez-Horta S, Fernandez de Bobadilla R, Perez J, et al
    Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.
    Mov Disord. 2015 Sep 26. doi: 10.1002/mds.26432.
    PubMed     Text format     Abstract available


  491. HAM JH, Lee JJ, Kim JS, Lee PH, et al
    Is Dominant-Side Onset Associated With a Better Motor Compensation in Parkinson's Disease?
    Mov Disord. 2015 Sep 26. doi: 10.1002/mds.26418.
    PubMed     Text format     Abstract available


  492. FARAG I, Sherrington C, Hayes A, Canning CG, et al
    Economic evaluation of a falls prevention exercise program among people With Parkinson's disease.
    Mov Disord. 2015 Sep 23. doi: 10.1002/mds.26420.
    PubMed     Text format     Abstract available


  493. SHAH N, Frey KA, L T M Muller M, Petrou M, et al
    Striatal and Cortical beta-Amyloidopathy and Cognition in Parkinson's Disease.
    Mov Disord. 2015 Sep 18. doi: 10.1002/mds.26369.
    PubMed     Text format     Abstract available


  494. SCHRAG A, Sauerbier A, Chaudhuri KR
    New clinical trials for nonmotor manifestations of Parkinson's disease.
    Mov Disord. 2015;30:1490-504.
    PubMed     Text format     Abstract available


  495. DU G, Liu T, Lewis MM, Kong L, et al
    Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Mov Disord. 2015 Sep 12. doi: 10.1002/mds.26417.
    PubMed     Text format     Abstract available


  496. QUINN EJ, Blumenfeld Z, Velisar A, Koop MM, et al
    Beta oscillations in freely moving Parkinson's subjects are attenuated during deep brain stimulation.
    Mov Disord. 2015 Sep 11. doi: 10.1002/mds.26376.
    PubMed     Text format     Abstract available


  497. SLOTNICK S, Ding Y, Glazman S, Durbin M, et al
    A novel retinal biomarker for Parkinson's disease: Quantifying the foveal pit with optical coherence tomography.
    Mov Disord. 2015 Sep 4. doi: 10.1002/mds.26411.
    PubMed     Text format     Abstract available


    August 2015
  498. GOLDMAN JG, Weintraub D
    Advances in the treatment of cognitive impairment in Parkinson's disease.
    Mov Disord. 2015 Aug 22. doi: 10.1002/mds.26352.
    PubMed     Text format     Abstract available


  499. MATA IF, Leverenz JB, Weintraub D, Trojanowski JQ, et al
    GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.
    Mov Disord. 2015 Aug 21. doi: 10.1002/mds.26359.
    PubMed     Text format     Abstract available


  500. CHAHINE LM, Weintraub D, Hawkins KA, Siderowf A, et al
    Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.
    Mov Disord. 2015 Aug 21. doi: 10.1002/mds.26373.
    PubMed     Text format     Abstract available


  501. CERASA A, Donzuso G, Morelli M, Mangone G, et al
    The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26378.
    PubMed     Text format     Abstract available


  502. BLOEM BR, de Vries NM, Ebersbach G
    Nonpharmacological treatments for patients with Parkinson's disease.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26363.
    PubMed     Text format     Abstract available


  503. METMAN LV, Slavin KV
    Advances in functional neurosurgery for Parkinson's disease.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26338.
    PubMed     Text format     Abstract available


  504. NALLS MA, Keller MF, Hernandez DG, Chen L, et al
    Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).
    Mov Disord. 2015 Aug 13. doi: 10.1002/mds.26374.
    PubMed     Text format     Abstract available


  505. POSTUMA RB, Adler CH, Dugger BN, Hentz JG, et al
    REM sleep behavior disorder and neuropathology in Parkinson's disease.
    Mov Disord. 2015 Aug 12. doi: 10.1002/mds.26347.
    PubMed     Text format     Abstract available


  506. RAJ KUMAR K
    Targeting glucocerebrosidase: Reduced enzymatic activity and Parkinson's disease.
    Mov Disord. 2015 Aug 11. doi: 10.1002/mds.26379.
    PubMed     Text format    


  507. SCHUFF N, Wu IW, Buckley S, Foster ED, et al
    Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.
    Mov Disord. 2015 Aug 11. doi: 10.1002/mds.26325.
    PubMed     Text format     Abstract available


  508. BRENNAN L, Siderowf A, Rubright JD, Rick J, et al
    Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire.
    Mov Disord. 2015 Aug 7. doi: 10.1002/mds.26339.
    PubMed     Text format     Abstract available


  509. PIHLSTROM L, Toft M
    Cumulative genetic risk and age at onset in Parkinson's disease.
    Mov Disord. 2015 Aug 3. doi: 10.1002/mds.26366.
    PubMed     Text format    


  510. VIRMANI T, Moskowitz CB, Vonsattel JP, Fahn S, et al
    Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease.
    Mov Disord. 2015 Aug 3. doi: 10.1002/mds.26346.
    PubMed     Text format     Abstract available


  511. MA Y, Johnston TH, Peng S, Zuo C, et al
    Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
    Mov Disord. 2015;30:1283-8.
    PubMed     Text format     Abstract available


    July 2015
  512. SCHRAG A
    A new scale for the assessment of pain in Parkinson's disease.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26353.
    PubMed     Text format    


  513. MISCHLEY LK, Leverenz JB, Lau RC, Polissar NL, et al
    A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26351.
    PubMed     Text format     Abstract available


  514. SERAJI-BOZORGZAD N, Bao F, George E, Krstevska S, et al
    Longitudinal study of the substantia nigra in Parkinson disease: A high-field H-MR spectroscopy imaging study.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26323.
    PubMed     Text format     Abstract available


  515. GESQUIERE-DANDO A, Guedj E, Loundou A, Carron R, et al
    A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26349.
    PubMed     Text format     Abstract available


  516. UDUPA K, Ghahremani A, Chen R
    Are we close to the advent of closed loop deep brain stimulation in Parkinson's disease?
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26343.
    PubMed     Text format    


  517. MENDES A, Goncalves A, Vila-Cha N, Moreira I, et al
    Appendectomy may delay Parkinson's disease Onset.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26311.
    PubMed     Text format     Abstract available


  518. RAMIREZ A
    Population-Based Genetic Studies: The Search for Causative Variants in Parkinson's Disease.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26341.
    PubMed     Text format    


  519. POSTUMA RB
    Can Parkinson's Disease Come From the Gut?
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26337.
    PubMed     Text format    


  520. WILLIAMS-GRAY C
    Seeing Is Believing: Alpha-Synuclein Oligomers in Parkinson's Disease Brain.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26335.
    PubMed     Text format    


  521. KALIA LV, Kalia SK, Lang AE
    Disease-modifying strategies for Parkinson's disease.
    Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26354.
    PubMed     Text format     Abstract available


  522. SWANSON CR, Berlyand Y, Xie SX, Alcalay RN, et al
    Plasma Apolipoprotein A1 Associates With Age at Onset and Motor Severity in Early Parkinson's Disease Patients.
    Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26290.
    PubMed     Text format     Abstract available


  523. DUNCAN GW, Firbank MJ, Yarnall AJ, Khoo TK, et al
    Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?
    Mov Disord. 2015 Jul 22. doi: 10.1002/mds.26312.
    PubMed     Text format     Abstract available


  524. REHMAN AF, Dhamija R, Williams ES, Barrett MJ, et al
    22q11.2 deletion syndrome presenting with early-onset Parkinson's disease.
    Mov Disord. 2015 Jul 21. doi: 10.1002/mds.26305.
    PubMed     Text format    


  525. OZ G
    MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
    Mov Disord. 2015 Jul 17. doi: 10.1002/mds.26322.
    PubMed     Text format    


  526. ZORKO N, Kojovic M, Flisar D, Pirtosek Z, et al
    Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.
    Mov Disord. 2015 Jul 17. doi: 10.1002/mds.26315.
    PubMed     Text format    


  527. LOU Y, Huang P, Li D, Cen Z, et al
    Altered brain network centrality in depressed Parkinson's disease patients.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26321.
    PubMed     Text format     Abstract available


  528. FERNANDEZ HH, Standaert DG, Chatamra K, Benesh JA, et al
    Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26316.
    PubMed     Text format    


  529. KESHAVARZIAN A, Green SJ, Engen PA, Voigt RM, et al
    Colonic bacterial composition in Parkinson's disease.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26307.
    PubMed     Text format     Abstract available


  530. BRUNDIN P, Atkin G, Lamberts JT
    Basic science breaks through: New therapeutic advances in Parkinson's disease.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26332.
    PubMed     Text format     Abstract available


  531. LOPANE G, Mellone S, Chiari L, Cortelli P, et al
    Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26313.
    PubMed     Text format     Abstract available


  532. BAIG F, Lawton M, Rolinski M, Ruffmann C, et al
    Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26281.
    PubMed     Text format     Abstract available


  533. SCHMITT I, Kaut O, Khazneh H, deBoni L, et al
    L-dopa increases alpha-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26319.
    PubMed     Text format     Abstract available


  534. STEELE JC, Wresch R, Hanlon SD, Keystone J, et al
    A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam.
    Mov Disord. 2015 Jul 7. doi: 10.1002/mds.26264.
    PubMed     Text format     Abstract available


  535. SANTANGELO G, Trojano L, Barone P, Vitale C, et al
    Cortical thickness in Parkinsonians with impulse control disorders: A comment.
    Mov Disord. 2015 Jul 7. doi: 10.1002/mds.26262.
    PubMed     Text format    


  536. BURCIU RG, Ofori E, Shukla P, Planetta PJ, et al
    Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2015 Jul 6. doi: 10.1002/mds.26294.
    PubMed     Text format     Abstract available


  537. DAVID FJ, Robichaud JA, Leurgans SE, Poon C, et al
    Exercise Improves Cognition in Parkinson's Disease: The PRET-PD Randomized, Clinical Trial.
    Mov Disord. 2015 Jul 6. doi: 10.1002/mds.26291.
    PubMed     Text format     Abstract available


  538. SCHEPERJANS F
    Reply to letter to the editor by Assoc. Prof. Yusuf Ozgur Cakmak, MD, PhD.
    Mov Disord. 2015;30:1151-3.
    PubMed     Text format    


    June 2015
  539. CURTZE C, Nutt JG, Carlson-Kuhta P, Mancini M, et al
    Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26269.
    PubMed     Text format     Abstract available


  540. MURATA M, Hasegawa K, Kanazawa I, Fukasaka J, et al
    Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26286.
    PubMed     Text format     Abstract available


  541. FRANCIOTTI R, Delli Pizzi S, Perfetti B, Tartaro A, et al
    Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26285.
    PubMed     Text format     Abstract available


  542. GEGG ME, Sweet L, Wang BH, Shihabuddin LS, et al
    No evidence for substrate accumulation in Parkinson brains with GBA mutations.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26278.
    PubMed     Text format     Abstract available


  543. ROCHESTER L, Espay AJ
    Multidisciplinary rehabilitation in Parkinson's disease: A milestone with future challenges.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26277.
    PubMed     Text format    


  544. ROSSI M, Perez-Lloret S, Millar Vernetti P, Drucaroff L, et al
    Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26276.
    PubMed     Text format     Abstract available


  545. FORJAZ MJ, Ayala A, Testa CM, Bain PG, et al
    Proposing a Parkinson's Disease-Specific Tremor Scale From the MDS-UPDRS.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26271.
    PubMed     Text format     Abstract available


  546. CHAUDHURI KR, Rizos A, Trenkwalder C, Rascol O, et al
    King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26270.
    PubMed     Text format     Abstract available


  547. WAKEMAN DR
    Autologous iPSC-Derived Dopamine Neuron Grafts Show Considerable Promise in a Nonhuman Primate Model of Parkinson's Disease.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26267.
    PubMed     Text format    


  548. MONTICONE M, Ambrosini E, Laurini A, Rocca B, et al
    In-patient multidisciplinary rehabilitation for Parkinson's disease: A randomized controlled trial.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26256.
    PubMed     Text format     Abstract available


  549. CERAVOLO R, Antonini A, Frosini D, De Iuliis A, et al
    Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26255.
    PubMed     Text format    


  550. SIMUNI T, Caspell-Garcia C, Coffey C, Chahine LM, et al
    Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26248.
    PubMed     Text format     Abstract available


  551. KOTAGAL V, Bohnen NI, Muller ML, Koeppe RA, et al
    Educational Attainment and Motor Burden in Parkinson's Disease.
    Mov Disord. 2015 Jun 10. doi: 10.1002/mds.26272.
    PubMed     Text format     Abstract available



  552. Abstracts of the Nineteenth International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2015;30 Suppl 1:S1-S642.
    PubMed     Text format    


  553. HORNYKIEWICZ O
    50 years of levodopa.
    Mov Disord. 2015;30:1008.
    PubMed     Text format    


  554. FAHN S
    Reply: Oleh Hornykiewicz's contribution to the l-dopa story.
    Mov Disord. 2015;30:1008-9.
    PubMed     Text format    


    May 2015
  555. CARECCHIO M, Schneider SA
    GTP cyclohydrolase 1 mutations and Parkinson's disease: New insights beyond DOPA-responsive dystonia.
    Mov Disord. 2015 May 27. doi: 10.1002/mds.26283.
    PubMed     Text format    


  556. BURN DJ
    The treatment of mild cognitive impairment associated with Parkinson's.
    Mov Disord. 2015 May 23. doi: 10.1002/mds.26245.
    PubMed     Text format    


  557. LOHMANN E, Coquel AS, Honore A, Gurvit H, et al
    A new F-box protein 7 gene mutation causing typical Parkinson's disease.
    Mov Disord. 2015 May 23. doi: 10.1002/mds.26266.
    PubMed     Text format     Abstract available


  558. ROSA M, Arlotti M, Ardolino G, Cogiamanian F, et al
    Adaptive deep brain stimulation in a freely moving parkinsonian patient.
    Mov Disord. 2015 May 21. doi: 10.1002/mds.26241.
    PubMed     Text format    


  559. VIZCARRA JA, Lang AE, Sethi KD, Espay AJ, et al
    Vascular Parkinsonism: Deconstructing a Syndrome.
    Mov Disord. 2015 May 21. doi: 10.1002/mds.26263.
    PubMed     Text format     Abstract available


  560. CAKMAK YO
    Provotella-derived hydrogen sulfide, constipation, and neuroprotection in Parkinson's disease.
    Mov Disord. 2015 May 13. doi: 10.1002/mds.26258.
    PubMed     Text format    


  561. NOYCE AJ, Mencacci NE, Schrag A, Bestwick JP, et al
    Web-based assessment of Parkinson's prodromal markers identifies GBA variants.
    Mov Disord. 2015 May 13. doi: 10.1002/mds.26249.
    PubMed     Text format    


    April 2015
  562. ERRO R
    VPS35 and EIF4G1 interactions and novel candidate genes for PD: from genes to pathways and back.
    Mov Disord. 2015;30:499.
    PubMed     Text format    


  563. FASANO A, Liu LW, Poon YY, Lang AE, et al
    Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model.
    Mov Disord. 2015;30:598-9.
    PubMed     Text format    


  564. NUTT JG
    Continuous levodopa infusion is better-for now.
    Mov Disord. 2015;30:443-5.
    PubMed     Text format    


  565. POEWE W, Hauser RA, Lang A
    Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
    Mov Disord. 2015;30:589-92.
    PubMed     Text format     Abstract available


    March 2015
  566. BLANCHET PJ, Pourcher E
    In memoriam: Paul J. Bedard, MD PhD: January 19, 1942-December 26, 2014.
    Mov Disord. 2015;30:299-300.
    PubMed     Text format    


  567. ZAVALA B, Zaghloul K, Brown P
    The subthalamic nucleus, oscillations, and conflict.
    Mov Disord. 2015;30:328-38.
    PubMed     Text format     Abstract available


  568. GOLDMAN JG, Holden S, Ouyang B, Bernard B, et al
    Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?
    Mov Disord. 2015;30:402-6.
    PubMed     Text format     Abstract available


    February 2015
  569. WEST AB
    Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
    Mov Disord. 2015;30:180-9.
    PubMed     Text format     Abstract available


  570. SHARP ME, Caccappolo E, Mejia-Santana H, Tang MX, et al
    The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.
    Mov Disord. 2015;30:278-83.
    PubMed     Text format     Abstract available


    January 2015
  571. BEAULIEU-BOIRE I, Lang AE
    Behavioral effects of levodopa.
    Mov Disord. 2015;30:90-102.
    PubMed     Text format     Abstract available


  572. AQUINO CC, Fox SH
    Clinical spectrum of levodopa-induced complications.
    Mov Disord. 2015;30:80-9.
    PubMed     Text format     Abstract available


  573. LEES AJ, Tolosa E, Olanow CW
    Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Mov Disord. 2015;30:19-36.
    PubMed     Text format     Abstract available


  574. POEWE W, Antonini A
    Novel formulations and modes of delivery of levodopa.
    Mov Disord. 2015;30:114-20.
    PubMed     Text format     Abstract available


  575. MOSHAROV EV, Borgkvist A, Sulzer D
    Presynaptic effects of levodopa and their possible role in dyskinesia.
    Mov Disord. 2015;30:45-53.
    PubMed     Text format     Abstract available


  576. GERSHANIK OS
    Improving L-dopa therapy: the development of enzyme inhibitors.
    Mov Disord. 2015;30:103-13.
    PubMed     Text format     Abstract available


  577. KO JH, Lerner RP, Eidelberg D
    Effects of levodopa on regional cerebral metabolism and blood flow.
    Mov Disord. 2015;30:54-63.
    PubMed     Text format     Abstract available


    December 2014
  578. BOLITHO SJ, Grunstein RR, Naismith SL, Melehan K, et al
    Reply: unified techniques are needed to diagnose REM sleep behavior disorder.
    Mov Disord. 2014;29:1836.
    PubMed     Text format    


  579. FANTINI ML, Figorilli M, Ferri R
    Rapid eye movement atonia is not rapid eye movement sleep behavior disorder.
    Mov Disord. 2014;29:1835.
    PubMed     Text format    


    September 2014
  580. YAMAKADO H
    Advance in PD research explored a new field on ubiquitin biology.
    Mov Disord. 2014;29:1243.
    PubMed     Text format    


  581. MONTGOMERY E, He H
    The FM/AM world is shaping the future of deep brain stimulation.
    Mov Disord. 2014;29:1327.
    PubMed     Text format    


  582. CHIASSERINI D, Persichetti E, Paciotti S, Beccari T, et al
    Lysosomal enzymes in PD: further evidence is needed.
    Mov Disord. 2014;29:1329.
    PubMed     Text format    


  583. FASANO A, Lozano AM
    Reply: the FM/AM world is shaping the future of deep brain stimulation.
    Mov Disord. 2014;29:1327-8.
    PubMed     Text format    


  584. CHEN H, Huang X, Guo X, Peddada S, et al
    Individual and joint prevalence of three nonmotor symptoms of PD in the US general population.
    Mov Disord. 2014;29:1316-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: